US20060160897A1 - Topical Use of Valproic Acid for the Prevention or Treatment of Skin Disorders - Google Patents

Topical Use of Valproic Acid for the Prevention or Treatment of Skin Disorders Download PDF

Info

Publication number
US20060160897A1
US20060160897A1 US11/275,258 US27525805A US2006160897A1 US 20060160897 A1 US20060160897 A1 US 20060160897A1 US 27525805 A US27525805 A US 27525805A US 2006160897 A1 US2006160897 A1 US 2006160897A1
Authority
US
United States
Prior art keywords
vpa
skin
derivative
treatment
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/275,258
Other languages
English (en)
Inventor
Pier Pelicci
Sergio Chimenti
Antonio Costanzo
Steven Nistico
Donatella Paolino
Saverio Minucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget Germany AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to TOPOTARGET GERMANY AG reassignment TOPOTARGET GERMANY AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PAOLINO, DONATELLA, CHIMENTI, SERGIO, COSTANZO, ANTONIO, NISTICO, STEVEN PAUL, MINUCCI, SAVERIO, PELICCI, PIER GIUSEPPE
Publication of US20060160897A1 publication Critical patent/US20060160897A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a topically applicable formulation containing Valproic Acid or a derivative thereof which can be used alone or in combination with topically applicable formulations of retinoids or of nuclear receptor ligands, or of chemotherapeutic agents (e.g. 5-Fluorouracil).
  • the formulation is useful for the topical treatment of cancerous skin disorders, such as Basal Cell Carcinoma, Squamous Cell Carcinoma, Keratoakantoma, Bowen Disease, cutaneous T-Cell Lymphoma and also for the topical treatment of pre-malignant lesions, and of inflammations of the skin and/or mucosa.
  • the invention also relates to the use of this topically applicable formulation for the protection from UV light and for the treatment of sun burn.
  • the invention includes the use of VPA for the manufacture of a clinically used medicament for the topical treatment of the human diseases listed above.
  • chromatin remodeling is a key step in the transcriptional activation of genes. Dynamic changes in the nucleosomal packaging of DNA must occur to allow transcriptional proteins to make contact with the DNA template.
  • One of the most important mechanisms influencing chromatin remodeling and gene transcription are the posttranslational modification of histones and other cellular proteins by acetylation and subsequent changes in chromatin structure (Davie, 1998, Curr Opin Genet Dev 8, 173-8; Kouzarides, 1999, Curr Opin Genet Dev 9, 40-8; Strahl and Allis, 2000, Nature 403, 41-4).
  • HAT histone acetyltransferase
  • HDAC histone deacetylase
  • PML-RAR the fusion protein associated with acute promyelocytic leukemia (APL) inhibits p53 through mediating deacetylation and degradation of p53, thus allowing APL blasts to evade p53 dependent cancer surveillance pathways.
  • APL acute promyelocytic leukemia
  • Expression of PML-RAR in hematopoietic precursor cells results in repression of p53 mediated transcriptional activation, and protection from p53-dependent apoptosis triggered by genotoxic stresses (X-rays, oxidative stress).
  • HDAC inhibitors implicating active recruitment of HDAC to p53 by PML-RAR as the mechanism underlying p53 inhibition (Insinga et al. 2003, manuscript submitted). Therefore, acetylation of proteins distinct from histones, such as acetylation of p53, plays a crucial role in the anti-tumor activity of HDAC inhibitors.
  • Nuclear hormone receptors are ligand-dependent transcription factors that control development and homeostasis through both positive and negative control of gene expression. Defects in these regulatory processes underlie the causes of many diseases and play an important role in the development of cancer. Many nuclear receptors, including T3R, RAR and PPAR, can interact with corepressors, such as N—CoR and SMRT, in the absence of ligand and thereby inhibit transcription. Furthermore, N—CoR has also been reported to interact with antagonist-occupied progesterone and estrogen receptors. Most interestingly, N—CoR and SMRT have been shown to exist in large protein complexes, which also contain mSin3 proteins and histone deacetylases (Pazin and Kadonaga, 1997; Cell 89, 325-8). Thus, the ligand-induced switch of nuclear receptors from repression to activation reflects the exchange of corepressor and coactivator complexes with antagonistic enzymatic activities.
  • Such corepressor complexes which contain HDAC activity, not only mediate repression by nuclear receptors, but also interact with additional transcription factors including Mad-1, BCL-6 and ETO. Many of these proteins play key roles in disorders of cell proliferation and differentiation (Pazin and Kadonaga, 1997, Cell 89, 325-8; Huynh and Bardwell, 1998, Oncogene 17, 2473-84; Wang, J. et al., 1998, Proc Natl Acad Sci U S A 95, 10860-5).
  • T3R for example was originally identified on the basis of its homology with the viral oncogene v-erbA, which in contrast to the wild type receptor does not bind ligand and functions as a constitutive repressor of transcription.
  • RARs have been associated with a number of human cancers, particularly acute promyelocytic leukemia (APL) and hepatocellular carcinoma.
  • APL acute promyelocytic leukemia
  • PML promyelocytic leukemia protein
  • PZF promyelocytic zinc finger protein
  • Another class comprises cyclic tetrapeptides, such as depsipeptide (FR901228-Fujisawa) used successfully in a phase II trial for the treatment of T-cell lymphomas (Piekarz et al., 2001, Blood 98, 2865-8). Furthermore, MS-27-275 (Mitsui Pharmaceuticals), a compound related to the class of benzamides, is now being tested in a phase I trial treating patients with hematological malignancies.
  • depsipeptide FR901228-Fujisawa
  • MS-27-275 Mitsubishi Pharmaceuticals
  • HDACs 1, 2, 3, and 8 which are homologues of the yeast RPD3 protein constitute class I.
  • HDACs 4, 5, 6, 7, 9, and 10 are related to the yeast Hda 1 protein and form class II.
  • yeast Sir2 protein has been identified forming a third class of deacetylases which are NAD dependent. All of these HDACs appear to exist in the cell as subunits of a plethora of multiprotein complexes.
  • class I and II HDACs have been shown to interact with transcriptional corepressors mSin3, N—CoR and SMRT which serve as bridging factors required for the recruitment of HDACs to transcription factors.
  • Valproic acid (VPA; 2-propyl-pentanoic acid) has multiple biological activities which depend on different molecular mechanisms of action:
  • VPA is an antiepileptic drug.
  • VPA is teratogenic. When used as an antiepileptic drug during pregnancy, VPA can induce birth defects (neural tube closure defects and other malformations) in a few percent of born children. In mice, VPA is teratogenic in the majority of mouse embryos when properly dosed.
  • VPA activates a nuclear hormone receptor (PPAR ⁇ ).
  • PPAR ⁇ nuclear hormone receptor
  • Several additional transcription factors are also derepressed but some factors are not significantly derepressed glucocorticoid receptor, PPAR ⁇ ).
  • VPA occasionally causes hepatotoxicity, which may depend on poorly metabolized esters with coenzyme A.
  • VPA is an inhibitor of HDACs.
  • VPA derivatives allowed to determine that the different activities are mediated by different molecular mechanisms of action. Teratogenicity and antiepileptic activity follow different modes of action because compounds could be isolated which are either preferentially teratogenic or preferentially antiepileptic (Nau et al., 1991, Pharmacol. Toxicol. 69, 310-321). Activation of PPAR ⁇ was found to be strictly correlated with teratogenicity (Lampen et al., 1999, Toxicol. Appl. Pharmacol. 160, 238-249) suggesting that, both, PPAR ⁇ activation and teratogenicity require the same molecular activity of VPA.
  • Antiepileptic and sedating activities follow different structure activity relationships and thus obviously depend on a primary VPA activity distinct from HDAC inhibition.
  • the mechanism of hepatotoxicity is poorly understood, and it is unknown whether it is associated with formation of the VPA-CoA ester.
  • HDAC inhibition appears not to require CoA ester formation.
  • Retinoic Acid belongs to a class of compounds known as retinoids, including but not limited to 9-cis RA, trans RA, all-trans RA, Tazaratone (Guenther, 2003, Am. J. Clin. Dermatol. 4, 197-202; Peris K et al., 1999, N Engl J Med 341, 1767-1768), that play key roles in regulating gene transcription and, therefore, govern multiple functions in the body, such as cell division and differentiation, immune response and embryonic development. They also control the development and spread of cancer cells, and some, including RA, can inhibit tumor growth by preventing cancer cell proliferation (Altucci and Gronemeyer, 2001, Nature Reviews Cancer 1, 181-193).
  • RARs RA receptors
  • RXRs retinoid X receptors
  • 9-cis RA is a high-affinity ligand for both RARs and RXRs, whereas trans-RA is a ligand for only RARs.
  • Retinoid receptors belong to a large steroid/thyroid receptor superfamily that mediate the biological effects of many hormones, vitamins and drugs.
  • RARs and RXRs act as transcriptional factors to positively or negatively regulate expression of target genes by binding to their response elements (RAREs) located in promoter regions of the target genes of an active chromatin structure and results in the transcription of target genes.
  • RAREs response elements located in promoter regions of the target genes of an active chromatin structure and results in the transcription of target genes.
  • liganded RAR can modulate the activity of other transcriptional factors, such as AP-1 (Pfahl 1993).
  • Activated retinoid receptors can inhibit the activity of AP-1, thereby regulating the expression of AP-1 target genes.
  • the inhibition of AP-1 activity is linked to the anti-proliferative effects of retinoids, and appears to be separable from their direct activation of transcription of retinoid-target genes.
  • RA derivatives For some time doctors have been using RA derivatives, to treat several cancers, particularly prostate cancer and leukemia, and they are now experimenting with the drug to treat breast cancer.
  • a typical treatment with RA seeks to activate RAR in order to switch on favorable genes.
  • the great drawback to RA is that it requires high levels of the medication in order to turn genes ‘on’ and ‘off,’ often triggering devastating and potentially fatal side effects (Altucci and Gronemeyer, 2001, Nature Reviews Cancer 1, 181-193).
  • RA or other retinoids such as Tazarotene (Guenther, 2003, Am. J. Clin. Dermatol. 4, 197-202) may also be used topically for the treatment of mild to moderate acne and sun damage (photoaged) skin. Retinoids have even been used to treat certain skin cancers, such as Basal Cell Carcinoma (Peris K et al., 1999, N Engl J Med 341, 1767-1768). After topical administration, RA appears to increase the rate of cell division and turnover. The number of cell layers in the outer portion of the skin is decreased. When pimples are present, they are more rapidly resolved. Topical RA is effective in reducing fine wrinkling, mottled hyperpigmentation, and roughness associated with overexposure to the sun. The results of treatment are not immediate and may be visible only after weeks to months. Discontinuation of treatment usually results in a loss of RA effects.
  • Basal cell carcinoma is not only the most common form of skin cancer, it is also the most common of all cancers affecting, e.g., 800,000 US Americans each year. These cancers arise in the basal cells, which are at the bottom of the epidermis (outer skin layer). Although the number of new cases has increased sharply each year in the last few decades, the average age of onset of the disease has steadily decreased. Until recently, those most often affected were older people, particularly men who had worked outdoors. However, today more women are getting BCC's than in the past; nonetheless, men still outnumber them greatly.
  • Predisposing factors for BCC include ultraviolet radiation, ionizing radiation, arsenic, inherited conditions, such as xeroderma pigmentosum and basal cell nevus syndrome, vaccinations, burns, and scars.
  • the typical lesion is a smooth-surfaced nodule with raised, pearly or translucent borders. Telangiectasias in the lesion are a common feature. Basal cell carcinomas vary in size from a few millimeters to several centimeters. Size can double in 6-12 months or growth may be slow. Eighty five percent occur on the head and neck with the nose being the most common site. Patients may report bleeding with minor trauma such as washing with a face cloth. This neoplasm is locally invasive and can be very destructive causing the loss of an eye, ear, or a nose, and may be lethal if it invades the brain.
  • Advanced skin cancer may be arbitrarily defined as tumors >2 cm, with invasion of bone muscle, or nerves, lymph node metastasis, or lesions that require removal of a cosmetic or functional unit.
  • the treatment for a BCC depends on its type, size and location, the number to be treated, and the preference or expertise of the doctor. Possibilities include:
  • Freezing use of liquid nitrogen for small superficial lesions. This is not a recommended treatment for BCC.
  • Curettage and cautery scraping of the tumor and cauterising the base. This is also not a recommended treatment for BBC.
  • Radiotherapy (X-ray treatment)—can be used in advanced lesions or where surgery is not suitable.
  • Topical chemotherapy topical application of a cream containing 5-Fluorouracil (5-FU) can be used especially for very large regions not treatable by surgery.
  • tumor therapies consist of the combinatorial treatment of patients with more than one anti-tumor therapeutic reagent. Examples are the combined use of irradiation treatment together with chemotherapeutic and/or cytotoxic reagents and more recently the combination of irradiation treatment with immunological therapies, such as the use of tumor cell specific therapeutic antibodies.
  • immunological therapies such as the use of tumor cell specific therapeutic antibodies.
  • the possibility to combine individual treatments with each other in order to identify such combinations which are more effective than the individual approaches alone requires extensive pre-clinical and clinical testing. It is not possible to predict which combinations will show an additive or even synergistic effect.
  • another purpose is the potential decrease of the doses of the individual components in the resulting combinations in order to decrease unwanted or harmful side effects caused by higher doses of the individual components.
  • Cytokines are a diverse group of soluble proteins and peptides which act as regulators to modulate the functional activities of individual cells and tissues. They are designed to induce an inflammatory reaction as a defense against foreign or altered endogenous substances. In many respects the biological activities of cytokines resemble those of classical hormones produced in specialized glandular tissues by acting at a systemic level to induce biological phenomena such as inflammation, acute phase reaction and autoimmunity. However, inappropriate activation of inflammatory responses is the underlying cause of many common diseases and inflammatory reactions are, therefore, also an important target for drug development.
  • cytokines accelerate inflammation and regulate a local or systemic inflammatory reaction either directly or through their ability to induce the synthesis of cellular adhesion molecules or other cytokines in certain cell types.
  • the major cytokines that are responsible for early responses are IL1, IL6 and TNF-alpha.
  • Other pro-inflammatory mediators include LIF, IFN-gamma, GM-CSF, IL11, IL12, IL18, and a variety of other chemokines.
  • cytokines are not restricted to the inflammatory process alone, but have also a leading role in the development and propagation of autoimmune diseases.
  • a classical example is rheumatoid arthritis where specific CD4+ T cells, most likely as a response to an unknown exogenous or endogenous antigen, induce an immune response in affected joints (Olsen et al., 2003, New England Journal of Medicine 350, 2167-79). Consequently, recruited monocytes, macrophages, and fibroblasts produce cytokines such as tumor necrosis factor- ⁇ (TNF- ⁇ ) and interleukin-1 within the synovial cavity. These cytokines are central to a damaging cascade, ultimately triggering the production of matrix metalloproteinases and osteoclasts, which results in irreversible damage to soft tissues and bones.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • interleukin-1 interleukin-1
  • TNF- ⁇ an inflammatory cytokine that is released by activated monocytes, macrophages, and T lymphocytes, promotes inflammatory responses that are important in the pathogenesis of rheumatoid arthritis.
  • Patients with rheumatoid arthritis have high concentrations of TNF- ⁇ in the synovial fluid.
  • TNF- ⁇ is localized to the junction of the inflammatory pannus and healthy cartilage, and high synovial fluid TNF- ⁇ concentrations are associated with the erosion of bone.
  • TNF antagonists appear to be among the most effective treatments available for rheumatoid arthritis.
  • the response is generally rapid, often occurring within a few weeks, although not all patients have a response.
  • TNF- ⁇ TNF- ⁇ tyrene-like fibrosis
  • Crohn's disease ulcerative colitis
  • Sjögren's syndrome scleroderma
  • psoriatic arthritis ankylosing spondylitis
  • refractory uveitis Behcet's disease
  • Behcet's disease adult-onset Still's disease
  • Wegener's granulomatosis
  • T cell mediated immune response is directed against keratinocytes.
  • T lymphocytes encounter the initiating antigen in the dermis or epidermis, and secrete type-1 cytokines (Th1), particularly interferon- ⁇ , interleukin 2, and TNF- ⁇ . These secretions result in proliferation and decreased maturation of keratinocytes and associated vascular changes. Secretion of other cytokines such as interleukin 8 contribute to the complete picture of psoriasis (Levani, 2004, The Lancet 361, 1197-1204).
  • Interferon- ⁇ is produced by natural killer cells and binds to the type II interferon receptor. It is less effective than interferon- ⁇ in activating natural killer cells and has less potent antiviral and antitumor effects.
  • interferon- ⁇ is the most potent inducer of macrophage activation and major histocompatibility class II molecules. It stimulates immunoglobulin secretion by B cells and promotes T-cell differentiation towards the T helper 1 type.
  • Interleukin 2 is secreted by activated T cells with antitumor activity. It is effective in the treatment of metastatic malignant melanoma and renal cell carcinoma. It induces T-cell proliferation, potentiates B-cell growth, and enhances natural killer cell and monocyte activation. The most common autoimmune side effect seen under interleukin 2 therapy is immune-mediated thyroid disease. Reversible thyroid dysfunction occurs frequently in patients with cancer who are treated with interleukin either alone or in conjunction with lymphokine-activated killer cells or interferon- ⁇ . In a study with interleukin 2 in patients with metastatic renal cell carcinoma, antithyroid antibodies were detected in 18% (60/329) of patients.
  • Interleukin 2 may potentiate a breakdown of immunologic tolerance to muscle-specific and tumor antigens, resulting in destruction of both tumor and muscle cells.
  • One patient with metastatic renal cell carcinoma treated with interleukin 2 and lymphokine-activated killer cells developed an acute exacerbation of systemic sclerosis. Serum levels of interleukin 2 and soluble interleukin 2 receptor are elevated in patients with systemic sclerosis and correlate with disease duration and activity.
  • It is an object of the present invention to provide a topical pharmaceutical composition for the prevention or treatment of skin disorders comprising (i) at least about 0.1% of an active agent selected from the group consisting of VPA and pharmaceutically acceptable salts thereof, and derivatives of VPA and pharmaceutically salts thereof; and (ii) a dermatologically acceptable carrier.
  • FIG. 1 shows that VPA potentiates Tazarotene (Taz) induced cell growth inhibition.
  • FIG. 1 depicts the results of growth assays performed on human immortalized keratinocytes (HaCaT cells), demonstrating that VPA used alone and Tazarotene, a Retinoic Acid derivative, used alone inhibit HaCaT cell growth and that the use of Tazarotene in combination with the histone deacetylase inhibitor VPA is even more effective at inhibiting cell growth than each drug used alone (NT: no treatment, Taz: Tazarotene, VPA1+Taz1: VPA 1 mM+Tazarotene 1 ⁇ M, VPA1+Taz2: VPA 1 mM+Tazarotene 2 ⁇ M).
  • NT no treatment
  • Taz Tazarotene
  • VPA1+Taz1 VPA 1 mM+Tazarotene 1 ⁇ M
  • VPA1+Taz2 VPA 1 m
  • FIG. 2 shows that VPA potentiates Retinoic Acid (RA) induced cell growth inhibition.
  • FIG. 2 shows that VPA and RA used alone inhibit growth of human immortalized keratinocytes (HaCaT cells) and that VPA potentiates Retinoic Acid induced cell growth inhibition in these cells when both drugs are used in combination (NT: no treatment, RA: Retinoic Acid, VPA1+RA1: VPA 1 mM+Retinoic Acid 1 ⁇ M, VPA1+RA2: VPA 1 mM+Retinoic Acid 2 ⁇ M).
  • NT no treatment
  • RA Retinoic Acid
  • VPA1+RA1 VPA 1 mM+Retinoic Acid 1 ⁇ M
  • VPA1+RA2 VPA 1 mM+Retinoic Acid 2 ⁇ M
  • FIG. 3 shows that VPA potentiates 5-Fluorouracil (5-FU) induced cell growth inhibition.
  • FIG. 3 shows that VPA and 5-FU alone inhibit growth of HaCaT cells and that combinations of 5-FU (used at the concentrations indicated) plus VPA are even more effective at inhibiting HaCaT cell growth than each drug used alone (NT: no treatment, 5-FU: 5-Fluorouracil, VPA is used in combination with 5-FU at a concentration of 1 mM).
  • FIG. 4 shows that VPA induces cell cycle arrest of human keratinocytes.
  • FIG. 4 indicates that VPA alone induces cell cycle arrest in human immortalized keratinocytes (HaCaT cells).
  • FIG. 5 shows that VPA potentiates Tazarotene induced apoptosis.
  • FIG. 5 demonstrates that Tazarotene and VPA used alone induces apoptosis of HaCaT cells and that combinations of Tazarotene plus VPA are even more effective at inducing apoptosis in these cells, than each drug used alone (NT: no treatment, Taz: Tazarotene, VPA1+Taz1: VPA 1 mM+Tazarotene 1 ⁇ M, VPA1+Taz2: VPA 1 mM+Tazarotene 2 ⁇ M).
  • FIG. 6 shows that VPA topically applied at 3% (w/w) permeates human skin.
  • FIG. 6 shows the time dependent manner of permeation of human skin with VPA topically applied at 3% (w/w).
  • FIG. 7 shows that VPA induces histone H4 acetylation in keratinocytes.
  • FIG. 7 shows the VPA-induced histone H4 acetylation in HaCaT cells in a dose dependent manner.
  • FIG. 8 shows that VPA topically applied at 3% (w/w) induces skin cell acetylation in mice.
  • FIG. 8 depicts the histone H4 acetylation in skin cells of mice treated with VPA topically applied at 3% (w/w).
  • FIG. 9 shows that VPA topically applied at 3% (w/w) induces skin cell acetylation in mice.
  • FIG. 9 shows the acetylation of histone H4 in skin cells of mice induced by topical application of VPA at 3% (w/w) at a higher magnification compared to the presentation in FIG. 8 .
  • FIG. 10 shows that VPA topically applied at 3% (w/w) induces acetylation of BCC nuclei.
  • FIG. 10 shows the induction of acetylation of histone H4 in human Basal Cell Carcinoma (BCC) nuclei after topical application of VPA at 3% (w/w).
  • FIG. 11 shows that VPA topically applied at 3% (w/w) potentiates the effects of Tazarotene in the treatment of superficial BCC's.
  • FIG. 11 shows examples of three representative patients before treatment and after 6 weeks of combined topical treatment with Tazarotene applied at 0.1% (w/w) and with VPA applied at 3% (w/w).
  • FIG. 12 shows the modulation of inflammatory cytokines by TSA and VPA in human keratinocytes and peripheral blood lymphocytes.
  • FIG. 12 shows mRNA expression modulation of immunologically relevant genes such as inflammatory cytokines by HDAC inhibitors after stimulation with LPS or PMA/Ion (Example 12).
  • FIG. 13 shows the modulation of inflammatory cytokines by different HDAC inhibitors.
  • FIG. 13 shows mRNA expression modulation of immunologically relevant genes such as inflammatory cytokines by HDAC inhibitors after stimulation with PMA/Ion (Example 12).
  • FIG. 14 shows the modulation of inflammatory cytokines by HDAC inhibitors in peripheral blood lymphocytes.
  • FIG. 14 shows mRNA expression modulation of immunologically relevant genes such as inflammatory cytokines by HDAC inhibitors after CD3/CD28 stimulation (Example 12).
  • FIG. 15 shows the modulation of IL-2 and TNF- ⁇ expression by HDAC inhibitors in peripheral blood lymphocytes.
  • FIG. 15 shows protein expression modulation of immunologically relevant genes such as inflammatory cytokines by HDAC inhibitors after CD3/CD28 stimulation (Example 12).
  • FIG. 16 shows the modulation of IL-2 and TNF- ⁇ expression by HDAC inhibitors in peripheral blood lymphocytes stimulated with PMA/ION and CD3/CD28 mAbs.
  • FIG. 16 shows protein expression modulation of immunologically relevant genes such as inflammatory cytokines by HDAC inhibitors (Example 12).
  • FIG. 17 shows the VPA treatment schedule of a patient from a phase I/II trial.
  • FIG. 17 shows a clinical therapy schedule using the HDAC inhibitor VPA in a cancer patient (Example 13).
  • FIG. 18 shows that VPA induces histone hyperacetylation and regulation of marker genes in peripheral blood from patients from a phase I/II trial.
  • FIG. 18 shows the successful induction of histone acetylation and down regulation of the HDAC-2 protein in periperal blood cells of a patient treated with the HDAC inhibitor VPA according to the treatment schedule depicted in FIG. 17 (Example 13).
  • FIG. 19 shows the modulation of inflammatory cytokines by VPA from a patient in a phase I/II trial.
  • FIG. 19 shows the successful mRNA and protein expression modulation of immunologically relevant genes such as inflammatory cytokines by using the HDAC inhibitor VPA in a patient according to the treatment schedule depicted in FIG. 17 after CD3/CD28 stimulation (Example 13).
  • the present invention aims at providing an improved composition for the prevention or treatment of skin disorders.
  • VPA has been developed as a drug used for the treatment of epilepsia. Accordingly, VPA is used systemically, orally or intravenously, to allow the drug to pass the blood brain barrier to reach the epileptic target regions in the brain tissue in order to fulfill its anti-epileptic mission. Therefore, VPA is regarded as a drug that must be applied systemically in order to achieve its therapeutic effects.
  • VPA permeates human skin effectively, which is crucially required for any therapeutic compound to be used topically on skin. It was hypothesized by the inventors that VPA, by fulfilling this essential criteria for topical application, could thus be used for the topical treatment of cancer lesions of the skin.
  • VPA has in fact unexpected beneficial effects when used for the topical treatment of human skin diseases, e.g., human skin cancer.
  • human skin diseases e.g., human skin cancer.
  • the precise mode of action which is employed by VPA is not fully understood, but its potential to sensitize tumor cells for the activity of apoptosis, growth arrest and differentiation inducing compounds may be the basis of such an anti-tumor activity.
  • This surprising potential of VPA is expected to be based on its activity as an inhibitor of specific sets of enzymes having HDAC activity.
  • the invention therefore relates to a topical pharmaceutical composition for the prevention or treatment of skin disorders, comprising:
  • topical application means to apply or spread the compositions of the present invention onto the surface of the skin.
  • compositions or components thereof so described are suitable for use in contact with human skin without undue toxicity, incompatibility, instability, allergic response, and the like.
  • compositions of the present invention preferably comprise from about 0.1% to about 25%, more preferably from about 0.1% to about 6%, even more preferably from about 0.3% to about 5%, still more preferably from about 0.5% to about 4%, still more preferably from about 1% to about 4%, most preferably from about 2% to about 4%, of the active agent.
  • compositions of the present invention usually comprise from about 1% to about 99.9% of a dermatologically acceptable carrier within which the compositions of the present invention is incorporated to enable the active agent, as well as other optional actives, to be delivered to the skin at an appropriate concentration.
  • the composition of the invention is a semisolid at 25° C. and under atmospheric pressure.
  • the product form of the composition may be a cream, an ointment, a gel or a paste.
  • the product form of the composition may be a liquid dispersion, e.g. a lotion.
  • VPA potentiates the therapeutic effect of retinoids and chemotherapeutic drugs such as 5-Fluorouracil.
  • the composition therefore further comprises retinoic acid or a derivative thereof.
  • concentration of retinoic acid or the derivative in the composition is preferably from about 0.01% to about 1%, more preferably from about 0.05% to about 0.5% of the composition.
  • the retinoid is preferably selected from the group consisting of 9-cis retinoic acid, trans-retinoic acid, all-trans retinoic acid and Tazarotene.
  • the composition further comprises a chemotherapeutic drug such as 5-Fluorouracil.
  • concentration of the chemotherapeutic drug preferably is from about 0.1% to about 10%, more preferably from about 1% to about 10% of the composition.
  • the carrier is not a solution.
  • the carrier is a cream, a paste, an ointment, a lotion or a gel.
  • VPA a pharmaceutically acceptable salt thereof, a derivative of VPA or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a skin disorder wherein a medicament comprising at least about 0.1% VPA or derivative thereof is topically applied to the skin of an individual in need thereof.
  • the skin disorder preferably is a disease of the human skin in which induction of hyperacetylation of proteins has a beneficial therapeutic effect for patients.
  • the skin disorder may be a skin tumor, e.g., Basal Cell Carcinoma, Squamous cell carcinoma, Keratoakantoma, Bowen disease and cutaneous T-Cell Lymphoma.
  • the skin disorder may be a pre-neoplastic skin disease such as Actinic keratosis.
  • VPA or its derivative may be used for the treatment of inflammations of the skin and/or mucosa.
  • inflammations of the skin and/or mucosa are Psoriasis, Ichtiosis and Acne.
  • the skin disorder may also be sun damaged skin (photoaged skin, sun burn).
  • VPA or the derivative thereof according to the present invention may be combined with an established anti-cancer therapy.
  • VPA or the derivative thereof and the established cancer therapy may be applied simultaneously or successively (at different time points).
  • VPA or the derivative thereof and the further active may be administered simultaneously or successively (at different time points).
  • Further actives include inhibitors of histone deacetylases which are different to VPA, including but not limited to compounds such as NVP-LAQ824 (Novartis), Trichostatin A, Suberoyl anilide hydroxamic acid (Aton), CBHA (ATON), Pyroxamide (Aton), Scriptaid (Johns Hopkins), CI-994 (Pfizer), CG-1521 (CircaGen), Chlamydocin (Janssen), Biaryl hydroxamate, e.g., A-161906 (Abbott), Bicyclic aryl-N-hydroxycarboxamides (Kansai University), PXD-101 (Prolifix), Sulfonamide hydroxamic acid (MethylGene), TPX-HA analogue (CHAP) (Japan Energy), Oxamflatin, Trap
  • VPA or the derivative thereof may be combined with administration/application of chemotherapeutic or cytotoxic drugs (e.g. 5-FU), differentiation inducing drugs (e.g. vitamin D, vitamin D derivatives, retinoids, receptor binding agents such as imiquimode), radiation therapy (e.g. x-rays or gamma rays), immunological approaches (antibody therapy, vaccination), combined immunotherapeutic/cytotoxic approaches (e.g. antibodies conjugated with cytotoxic components), and the like.
  • chemotherapeutic or cytotoxic drugs e.g. 5-FU
  • differentiation inducing drugs e.g. vitamin D, vitamin D derivatives, retinoids, receptor binding agents such as imiquimode
  • radiation therapy e.g. x-rays or gamma rays
  • immunological approaches antibody therapy, vaccination
  • combined immunotherapeutic/cytotoxic approaches e.g. antibodies conjugated with cytotoxic components
  • VPA or its derivative potentiates orally applied retinoid activity in neoplastic and non-neoplastic skin diseases including skin tumors; Basal Cell Carcinoma; Squamous cell carcinoma; Keratoakantoma; Bowen disease; cutaneous T-Cell Lymphoma; Actinic keratosis; Psoriasis; Ichtiosis; Acne; other inflammatory skin diseases by topical application of VPA alone.
  • the invention provides a topically applicable formulation of a medicament containing Valproic Acid or derivatives thereof used alone or in combination with retinoids, with nuclear receptor ligands or with chemotherapeutic agents, such as 5-FU, for the topical treatment of cancer, pre-malignant skin lesions, and inflammations of the skin/mucosa.
  • chemotherapeutic agents such as 5-FU
  • one aspect of the present invention is the use of a topically applicable formulation containing VPA or derivatives thereof used alone or in combination with retinoids or with 5-Fluorouracil (5-FU) for a topical treatment of a variety of human cancers, pre-malignant skin lesions or inflammations of the skin/mucosa, and for the treatment of sun burn.
  • the anti-tumoral activity of combinatorial topical treatments compared to the use of each component alone can thus be increased and—if desired—the doses of the individual components of such combinatorial treatments may be lowered in order to decrease unwanted side effects related to treatment with the individual drugs alone.
  • the invention also concerns the use of VPA or a derivative thereof for the manufacture of a medicament for a topical treatment of diseases as listed above.
  • VPA VPA derived from carboxylic acids or carboxylic acid derivatives as described by formula I
  • R 1 and R 2 independently are a linear or branched, saturated or unsaturated aliphatic C 3-25 hydrocarbon chain which optionally comprises one or several heteroatoms and which may be substituted, R 3 is hydroxyl, halogen, alkoxy or an optionally alkylated amino group.
  • R 1 and R 2 residues give rise to chiral compounds.
  • one of the stereoisomers has a stronger teratogenic effect than the other one (Nau et al., 1991, Pharmacol. Toxicol. 69, 310-321) and the more teratogenic isomer more efficiently activates PPAR ⁇ (Lampen et al, 1999). Therefore, this isomer can be expected to inhibit HDACs more strongly (PCT/EP01/07704).
  • the present invention encompasses the racemic mixtures of the respective compounds and in particular the more active isomers.
  • the hydrocarbon chains R 1 and R 2 may comprise one or several heteroatoms (e.g. O, N, S) replacing carbon atoms in the hydrocarbon chain. This is due to the fact that structures very similar to that of carbon groups may be adopted by heteroatom groups when the heteroatoms have the same type of hybridization as a corresponding carbon group.
  • heteroatoms e.g. O, N, S
  • R 1 and R 2 may be substituted. Possible substituents include hydroxyl, amino, carboxylic and alkoxy groups as well as aryl and heterocyclic groups.
  • R 1 and R 2 independently comprise 3 to 10, more preferably 4 to 10 or 5 to 10 carbon atoms. It is also preferred that R 1 and R 2 independently are saturated or comprise one double bond or one triple bond.
  • one of the side chains (R 1 ) may preferably contain sp 1 hybridized carbon atoms in position 2 and 3 or heteroatoms which generate a similar structure. This side chain should comprise 3 carbon or heteroatoms but longer chains may also generate HDAC-inhibiting molecules.
  • inclusion of aromatic rings or heteroatoms in R 2 is considered to generate compounds with HDAC inhibitory activity because the catalytic site of the HDAC protein apparently accommodates a wide variety of binding molecules.
  • HDAC inhibitors also compounds which have previously been disregarded as suitable antiepileptic agents are considered as HDAC inhibitors (PCT/EP01/07704).
  • HDAC inhibitors PCT/EP01/07704
  • compounds having a propinyl residue as R 1 and residues of 7 or more carbons as R 2 are considered (Lampen et al, 1999).
  • the group “COR 3 ” is a carboxylic group. Also derivatization of the carboxylic group has to be considered for generating compounds with potential HDAC inhibitory activity. Such derivatives may be halides (e.g. chlorides), esters or amides.
  • R 3 is alkoxy
  • the alkoxy group comprises 1 to 25, preferably 1-10 carbon atoms.
  • R 3 is a mono- or di-alkylated amino group
  • the alkyl substituents comprise 1 to 25, preferably 1-10 carbon atoms.
  • compositions can be used for the formulation.
  • substances can be used which are metabolized to a compound as defined in formula I in the human organism or which lead to the release of a compound as defined in formula I for example by ester hydrolysis.
  • the invention concerns the use of an a-carbon branched carboxylic acid as described in formula I or of a pharmaceutically acceptable salt thereof as an inhibitor of an enzyme having histone deacetylase activity and its use in the topical therapy of cancer, wherein R 1 is a linear or branched, saturated or unsaturated, aliphatic C 5-25 hydrocarbon chain, R 2 independently is a linear or branched, saturated or unsaturated, aliphatic C 2-25 hydrocarbon chain, but not —CH 2 —CH ⁇ CH 2 , —CH 2 —C ⁇ CH or —CH 2 —CH 2 —CH 3 , R 1 and R 2 are optionally substituted with hydroxyl, amino, carboxylic, alkoxy, aryl and/or heterocyclic groups, and R 3 is hydroxyl.
  • the invention concerns the use of an a-carbon branched carboxylic acid as described in formula I or of a pharmaceutically acceptable salt thereof for the topical therapy of cancer, wherein R 1 is a linear or branched, saturated or unsaturated, aliphatic C 3-25 hydrocarbon chain, and R 2 independently is a linear or branched, saturated or unsaturated, aliphatic C 3-25 hydrocarbon chain, R 1 or R 2 comprise one or several heteroatoms (e.g. O, N, S) replacing carbon atoms in the hydrocarbon chain, R 1 and R 2 are optionally substituted with hydroxyl, amino, carboxylic, alkoxy, aryl and/or heterocyclic groups, and R 3 is hydroxyl.
  • R 1 is a linear or branched, saturated or unsaturated, aliphatic C 3-25 hydrocarbon chain
  • R 2 independently is a linear or branched, saturated or unsaturated, aliphatic C 3-25 hydrocarbon chain
  • R 1 or R 2 comprise one or several heteroatoms (e.
  • R 1 and R 2 do not comprise an ester group (—CO—O—).
  • R 1 and R 2 may be hydrocarbon chains comprising no heteroatoms O, N or S.
  • the compounds which are most preferably used according to the present invention are VPA and/or 4-yn VPA.
  • the present invention provides novel possibilities to treat various human diseases.
  • a combinatorial treatment is considered to generate superior therapeutic success in patients than the corresponding therapeutic drugs used on their own.
  • aspects of the present invention include the combination of compounds of formula I with, but not restricted to, therapeutic principles currently in clinical use or in clinical development, such as
  • chemotherapeutic or cytotoxic drugs e.g. 5-FU
  • differentiation inducing drugs e.g. vitamin D, vitamin D derivatives, retinoids, receptor binding agents such as imiquimode
  • Radiation therapy e.g. x-rays or gamma rays
  • immunotherapeutic/cytotoxic approaches e.g. antibodies conjugated with cytotoxic components
  • compositions of the present invention comprise from about 1% to about 99.9% of a dermatologically acceptable carrier within which the compositions of the present invention is incorporated to enable the active agent, as well as other optional actives, to be delivered to the skin at an appropriate concentration.
  • the carrier may contain one or more dermatologically acceptable solid, semi-solid or liquid fillers, diluents, solvents, extenders and the like.
  • the carrier may be solid, semi-solid or liquid. Preferred carriers are substantially semi-solid.
  • the carrier can itself be inert or it can possess dermatological benefits of its own. Concentrations of the carrier can vary with the carrier selected and the intended concentrations of the active agent and optional components.
  • Suitable carriers include conventional or otherwise known carriers that are dermatologically acceptable.
  • the carrier should also be physically and chemically compatible with the essential components described herein, and should not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention.
  • Preferred components of the compositions of this invention should be capable of being comingled in a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations.
  • the type of carrier utilized in the present invention depends on the type of product form desired for the composition.
  • the topical compositions useful in the subject invention may be made into a wide variety of product forms such as are known in the art. These include, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, oils, foams, powders and pastes. These product forms may comprise several types of carriers including, but not limited to, solutions, aerosols, emulsions, gels, solids, and liposomes.
  • Preferred carriers contain a dermatologically acceptable, hydrophilic diluent.
  • hydrophilic diluent includes materials in which the particulate material can be dispersed, dissolved, or otherwise incorporated.
  • hydrophilic diluents are water, organic hydrophilic diluents such as lower monovalent alcohols (e.g., C 1 -C 4 ) and low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g., Molecular Weight 200-600 g/mole), polypropylene glycol (e.g., Molecular Weight 425-2025 g/mole), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, ether propanol, ethoxylated ethers, propoxylated
  • Solutions according to the subject invention typically include a dermatologically acceptable hydrophilic diluent. Solutions useful in the subject invention preferably contain from about 60% to about 99.99% of the hydrophilic diluent.
  • Aerosols according to the subject invention can be formed by adding a propellant to a solution such as described above.
  • exemplary propellants include chloro-fluorinated lower molecular weight hydrocarbons. Aerosols are typically applied to the skin as a spray-on product.
  • Preferred carriers comprise an emulsion comprising a hydrophilic phase comprising a hydrophilic component, e.g., water or other hydrophilic diluent, and a hydrophobic phase comprising a hydrophobic component, e.g., a lipid, oil or oily material.
  • a hydrophilic phase will be dispersed in the hydrophobic phase, or vice versa, to form respectively hydrophilic or hydrophobic dispersed and continuous phases, depending on the composition ingredients.
  • the term “dispersed phase” is a term well-known to one skilled in the art which means that the phase exists as small particles or droplets that are suspended in and surrounded by a continuous phase.
  • the dispersed phase is also known as the internal or discontinuous phase.
  • the emulsion may be or comprise (e.g., in a triple or other multi-phase emulsion) an oil-in-water emulsion or a water-in-oil emulsion such as a water-in-silicone emulsion.
  • Oil-in-water emulsions typically comprise from about 1% to about 50% of the dispersed hydrophobic phase and from about 1% to about 98% of the continuous hydrophilic phase; water-in-oil emulsions typically comprise from about 1% to about 98% of the dispersed hydrophilic phase and from about 1% to about 50% of the continuous hydrophobic phase.
  • the emulsion may also comprise a gel network. Preferred emulsions are further described below.
  • compositions of the subject invention may comprise a dermatologically acceptable emollient.
  • emollients may contain from about 2% to about 50% of the emollient.
  • Emollients tend to lubricate the skin, increase the smoothness and suppleness of the skin, prevent or relieve dryness of the skin, and/or protect the skin.
  • Emollients are typically water-immiscible, oily or waxy materials. Non-limiting examples of emollients are described herein.
  • Lotions and creams according to the present invention preferably comprise a solution carrier system and one or more emollients.
  • Lotions typically comprise from about 1% to about 20%, preferably from about 5% to about 10%, of emollient; from about 50% to about 90%, preferably from about 60% to about 80%, water.
  • a cream typically comprises from about 5% to about 50%, preferably from about 10% to about 20%, of emollient; and from about 45% to about 85%, preferably from about 50% to about 75%, water.
  • Ointments of the present invention may comprise a simple carrier base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous); absorption ointment bases which absorb water to form emulsions; or water soluble carriers, e.g., a water soluble solution carrier.
  • Ointments may further comprise a thickening agent.
  • an ointment may comprise from about 2% to about 10% of an emollient; and from about 0.1% to about 2% of a thickening agent.
  • Non-limiting examples of thickening agents are described herein.
  • compositions of the present invention comprise an emulsion.
  • Emulsions of the present invention may contain one or more of the following:
  • Emulsions according to the present invention contain a hydrophobic phase comprising a lipid, oil, oily or other hydrophobic component.
  • the compositions of the present invention preferably comprise from about 1% to about 50%, preferably from about 1% to about 30%, and more preferably from about 1% to about 10% by weight of the composition of a hydrophobic component.
  • the hydrophobic component may be derived from animals, plants, or petroleum and may be natural or synthetic (i.e., man-made).
  • Preferred hydrophobic components are substantially water-insoluble, more preferably essentially water-insoluble.
  • suitable hydrophobic components include those selected from the group consisting of:
  • Mineral oil which is also known as petrolatum liquid, is a mixture of liquid hydrocarbons obtained from petroleum. See The Merck Index, Tenth Edition, Entry 7048, p. 1033 (1983).
  • Petrolatum which is also known as petroleum jelly, is a colloidal system of nonstraight-chain solid hydrocarbons and high-boiling liquid hydrocarbons, in which most of the liquid hydrocarbons are held inside the micelles. See The Merck Index, Tenth Edition, Entry 7047, p. 1033 (1983); Schindler, Drug. Cosmet. Ind., 89, 36-37, 76, 78-80, 82 (1961).
  • Straight and branched chain hydrocarbons having from about 7 to about 40 carbon atoms.
  • hydrocarbon materials include dodecane, isododecane, squalane, cholesterol, hydrogenated polyisobutylene, docosane, hexadecane, isohexadecane.
  • C7-C40 isoparaffins which are C7-C40 branched hydrocarbons, e.g., C13-C14 isoparaffin.
  • C1-C30 alcohol esters of C1-C30 carboxylic acids and of C2-C30 dicarboxylic acids including straight and branched chain materials as well as aromatic derivatives (as used herein in reference to the hydrophobic component, mono- and poly-carboxylic acids include straight chain, branched chain and aryl carboxylic acids).
  • Nonlimiting examples include diisopropyl sebacate, diisopropyl adipate, isopropyl myristate, isopropyl palmitate, methyl palmitate, myristyl propionate, 2-ethylhexyl palmitate, isodecyl neopentanoate, di-2-ethylhexyl maleate, cetyl palmitate, myristyl myristate, stearyl stearate, isopropyl stearate, methyl stearate, cetyl stearate, behenyl behenrate, dioctyl maleate, dioctyl sebacate, diisopropyl adipate, cetyl octanoate, diisopropyl dilinoleate.
  • mono-, di- and tri-glycerides of C1-C30 carboxylic acids e.g., caprilic/capric triglyceride, PEG-6 caprylic/capric triglyceride, PEG-8 caprylic/capric triglyceride.
  • alkylene glycol esters of C1-C30 carboxylic acids e.g., ethylene glycol mono- and di-esters, and propylene glycol mono- and di-esters of C1-C30 carboxylic acids e.g., ethylene glycol distearate.
  • esters are derived from a sugar or polyol moiety and one or more carboxylic acid moieties. Depending on the constituent acid and sugar, these esters can be in either liquid or solid form at room temperature.
  • liquid esters include: glucose tetraoleate, the glucose tetraesters of soybean oil fatty acids (unsaturated), the mannose tetraesters of mixed soybean oil fatty acids, the galactose tetraesters of oleic acid, the arabinose tetraesters of linoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, the sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate, sucrose pentaoletate, sucrose hexaoleate, sucrose hepatoleate, sucrose octaoleate, and mixtures thereof.
  • solid esters examples include: sorbitol hexaester in which the carboxylic acid ester moieties are palmitoleate and arachidate in a 1:2 molar ratio; the octaester of raffinose in which the carboxylic acid ester moieties are linoleate and behenate in a 1:3 molar ratio; the heptaester of maltose wherein the esterifying carboxylic acid moieties are sunflower seed oil fatty acids and lignocerate in a 3:4 molar ratio; the octaester of sucrose wherein the esterifying carboxylic acid moieties are oleate and behenate in a 2:6 molar ratio; and the octaester of sucrose wherein the esterifying carboxylic acid moieties are laurate, linoleate and behenate in a 1:3:4 molar ratio.
  • a preferred solid material is sucrose polyester in which the degree of esterification is 7-8, and in which the fatty acid moieties are C18 mono- and/or di-unsaturated and behenic, in a molar ratio of unsaturates:behenic of 1:7 to 3:5.
  • a particularly preferred solid sugar polyester is the octaester of sucrose in which there are about 7 behenic fatty acid moieties and about 1 oleic acid moiety in the molecule.
  • Other materials include cottonseed oil or soybean oil fatty acid esters of sucrose.
  • Organopolysiloxane oils may be volatile, non-volatile, or a mixture of volatile and non-volatile silicones.
  • the term “nonvolatile” as used in this context refers to those silicones that are liquid under ambient conditions.
  • the term “volatile” as used in this context refers to all other silicone oils.
  • Suitable organopolysiloxanes can be selected from a wide variety of silicones spanning a broad range of volatilities and viscosities. Nonvolatile polysiloxanes are preferred.
  • suitable organopolysiloxane oils include polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes.
  • organopolysiloxanes selected from the group consisting of polyalkylsiloxanes, alkyl substituted dimethicones, cyclomethicones, trimethylsiloxysilicates, dimethiconols, polyalkylaryl siloxanes, and mixtures thereof. More preferred for use herein are polyalkylsiloxanes and cyclomethicones. Preferred among the polyalkylsiloxanes are dimethicones, as described in U.S. Pat. No. 5,968,528.
  • Vegetable oils and hydrogenated vegetable oils examples include safflower oil, castor oil, coconut oil, cottonseed oil, menhaden oil, palm kernel oil, palm oil, peanut oil, soybean oil, rapeseed oil, linseed oil, rice bran oil, pine oil, sesame oil, sunflower seed oil, hydrogenated safflower oil, hydrogenated castor oil, hydrogenated coconut oil, hydrogenated cottonseed oil, hydrogenated menhaden oil, hydrogenated palm kernel oil, hydrogenated palm oil, hydrogenated peanut oil, hydrogenated soybean oil, hydrogenated rapeseed oil, hydrogenated linseed oil, hydrogenated rice bran oil, hydrogenated sesame oil, hydrogenated sunflower seed oil, and mixtures thereof.
  • animal fats and oils e.g., lanolin and derivatives thereof, cod liver oil.
  • C4-C20 alkyl ethers of polypropylene glycols are also useful.
  • C1-C20 carboxylic acid esters of polypropylene glycols include di-C8-C30 alkyl ethers.
  • Nonlimiting examples of these materials include PPG-14 butyl ether, PPG-15 stearyl ether, dioctyl ether, dodecyl octyl ether, and mixtures thereof.
  • Emulsions of the present invention also comprise a hydrophilic component, e.g., water or other hydrophilic diluent.
  • the hydrophilic phase can thus comprise water, or a combination of water and one or more water soluble or dispersible ingredients. Hydrophilic components comprising water are preferred.
  • Emulsions and other topical compositions of the present invention may comprise a variety of other ingredients such as disclosed herein. As will be understood by the skilled artisan, a given component will distribute primarily into either a hydrophilic phase or hydrophobic phase, depending on the hydrophilicity of the component in the composition.
  • Emulsions of the present invention preferably include one or more compounds selected from emulsifiers, surfactants, structuring agents, and thickeners.
  • the emulsion may contain an emulsifier and/or surfactant, generally to help disperse and suspend the discontinuous phase within the continuous phase.
  • an emulsifier and/or surfactant generally to help disperse and suspend the discontinuous phase within the continuous phase.
  • emulsifiers/surfactants can be employed.
  • Known or conventional emulsifiers/surfactants can be used in the composition, provided that the selected agent is chemically and physically compatible with essential components of the composition, and provides the desired dispersion characteristics.
  • Suitable agents include non-silicone-containing emulsifiers/surfactants, silicone emulsifiers/surfactants, and mixtures thereof.
  • the composition comprises a hydrophilic emulsifier or surfactant.
  • the compositions of the present invention preferably comprise from about 0.05% to about 5%, more preferably from about 0.05% to about 1% of at least one hydrophilic surfactant.
  • Preferred hydrophilic surfactants are selected from nonionic surfactants.
  • nonionic surfactants that are useful herein are those that can be broadly defined as condensation products of long chain alcohols, e.g. C8-30 alcohols, with sugar or starch polymers, i.e., glycosides.
  • long chain alcohols from which the alkyl group can be derived include decyl alcohol, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol, and the like.
  • Commercially available examples of these surfactants include decyl polyglucoside (available as APG 325 CS from Henkel) and lauryl polyglucoside (available as APG 600 CS and 625 CS from Henkel).
  • nonionic surfactants include the condensation products of alkylene oxides with fatty acids (i.e. alkylene oxide esters of fatty acids).
  • Other nonionic surfactants are the condensation products of alkylene oxides with fatty alcohols (i.e. alkylene oxide ethers of fatty alcohols).
  • Still other nonionic surfactants are the condensation products of alkylene oxides with both fatty acids and fatty alcohols [i.e. wherein the polyalkylene oxide portion is esterified on one end with a fatty acid and etherified (i.e. connected via an ether linkage) on the other end with a fatty alcohol].
  • Nonlimiting examples of these alkylene oxide derived nonionic surfactants include ceteth-6, ceteth-10, ceteth-12, ceteareth-6, ceteareth-10, ceteareth-12, steareth-6, steareth-10, steareth-12, PEG-6 stearate, PEG-10 stearate, PEG-100 stearate, PEG-12 stearate, PEG-20 glyceryl stearate, PEG-80 glyceryl tallowate, PEG-10 glyceryl stearate, PEG-30 glyceryl cocoate, PEG-80 glyceryl cocoate, PEG-200 glyceryl tallowate, PEG-8 dilaurate, PEG-10 distearate, and mixtures thereof.
  • Still other useful nonionic surfactants include polyhydroxy fatty acid amide surfactants.
  • nonionic surfactants are those selected from the group consisting of steareth-21, ceteareth-20, ceteareth-12, sucrose cocoate, steareth-100, PEG-100 stearate, and mixtures thereof.
  • nonionic surfactants suitable for use herein include sugar esters and polyesters, alkoxylated sugar esters and polyesters, C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated derivatives of C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated ethers of C1-C30 fatty alcohols, polyglyceryl esters of C1-C30 fatty acids, C1-C30 esters of polyols, C1-30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, and mixtures thereof.
  • Nonlimiting examples of these non-silicon-containing emulsifiers include: polyethylene glycol 20 sorbitan monolaurate (Polysorbate 20), polyethylene glycol 5 soya sterol, Steareth-20, Ceteareth-20, PPG-2 methyl glucose ether distearate, Ceteth-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, Polysorbate 60, glyceryl stearate, polyoxyethylene 20 sorbitan trioleate (Polysorbate 85), sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, PPG-2 methyl glucose ether distearate, PEG-100 stearate, and mixtures thereof.
  • Polysorbate 20 polyethylene glycol 5 soya sterol
  • Steareth-20 Ceteareth-20
  • emulsifier useful herein are fatty acid ester blends based on a mixture of sorbitan or sorbitol fatty acid ester and sucrose fatty acid ester.
  • the preferred fatty acid ester emulsifier is a blend of sorbitan or sorbitol C 16 -C 20 fatty acid ester with sucrose C 10 -C 16 fatty acid ester, especially sorbitan stearate and sucrose cocoate. This is commercially available from ICI under the trade name Arlatone 2121.
  • hydrophilic surfactants useful herein can alternatively or additionally include any of a wide variety of cationic, anionic, zwitterionic, and amphoteric surfactants such as are known in the art. See, e.g., McCutcheon's, Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation.
  • Exemplary cationic surfactants useful herein include those disclosed in U.S. Pat. No. 5,968,528.
  • the cationic surfactants useful herein include cationic ammonium salts such as quaternary ammonium salts, and amino-amides.
  • anionic surfactants are also useful herein. See e.g., U.S. Pat. No. 5,968,528.
  • anionic surfactants include the alkoyl isethionates (e.g., C 12 -C 30 ), alkyl and alkyl ether sulfates and salts thereof, alkyl and alkyl ether phosphates and salts thereof, alkyl methyl taurates (e.g., C 12 -C 30 ), and soaps (e.g., alkali metal salts, e.g., sodium or potassium salts) of fatty acids.
  • alkoyl isethionates e.g., C 12 -C 30
  • alkyl and alkyl ether sulfates and salts thereof alkyl and alkyl ether phosphates and salts thereof
  • alkyl methyl taurates e.g., C 12 -C 30
  • soaps e.g., alkal
  • amphoteric and zwitterionic surfactants are also useful herein.
  • amphoteric and zwitterionic surfactants which can be used in the compositions of the present invention are those which are broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably C 8 -C 18 ) and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • alkyl imino acetates examples are alkyl imino acetates, and iminodialkanoates and aminoalkanoates, imidazolinium and ammonium derivatives.
  • Other suitable amphoteric and zwitterionic surfactants are those selected from the group consisting of betaines, sultaines, hydroxysultaines, alkyl sarcosinates (e.g., C 12 -C 30 ), and alkanoyl sarcosinates.
  • Preferred emulsions of the present invention include a silicone containing emulsifier or surfactant.
  • silicone emulsifiers are useful herein. These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants.
  • Useful silicone emulsifiers include dimethicone copolyols. These materials are polydimethyl siloxanes which have been modified to include polyether side chains such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains, and polyether chains containing moieties derived from both ethylene oxide and propylene oxide.
  • dimethicone copolyols examples include alkyl-modified dimethicone copolyols, i.e., compounds which contain C2-C30 pendant side chains.
  • Still other useful dimethicone copolyols include materials having various cationic, anionic, amphoteric, and zwitterionic pendant moieties.
  • Nonlimiting examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers herein include polydimethylsiloxane polyether copolymers with pendant polyethylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed polyethylene oxide and polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed poly(ethylene)(propylene)oxide sidechains, polydimethylsiloxane polyether copolymers with pendant organobetaine sidechains, polydimethylsiloxane polyether copolymers with pendant carboxylate sidechains, polydimethylsiloxane polyether copolymers with pendant quaternary ammonium sidechains; and also further modifications of the preceding copolymers containing pendant C2-C30 straight, branched, or cyclic alky
  • dimethicone copolyols useful herein sold by Dow Corning Corporation are Dow Corning® 190, 193, Q2-5220, 2501 Wax, 2-5324 fluid, and 3225C (this later material being sold as a mixture with cyclomethicone). Cetyl dimethicone copolyol is commercially available as a mixture with polyglyceryl-4 isostearate (and) hexyl laurate and is sold under the tradename ABIL® WE-09 (available from Goldschmidt).
  • Cetyl dimethicone copolyol is also commercially available as a mixture with hexyl laurate (and) polyglyceryl-3 oleate (and) cetyl dimethicone and is sold under the tradename ABIL® WS-08 (also available from Goldschmidt).
  • dimethicone copolyols also include lauryl dimethicone copolyol, dimethicone copolyol acetate, dimethicone copolyol adipate, dimethicone copolyolamine, dimethicone copolyol behenate, dimethicone copolyol butyl ether, dimethicone copolyol hydroxy stearate, dimethicone copolyol isostearate, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyol phosphate, and dimethicone copolyol stearate.
  • Dimethicone copolyol emulsifiers useful herein are described, for example, in U.S. Pat. No. 5,968,528.
  • compositions hereof, and especially the emulsions hereof may contain a structuring agent.
  • Structuring agents are particularly preferred in the oil-in-water emulsions of the present invention.
  • the structuring agent assists in providing rheological characteristics to the composition which contribute to the stability of the composition.
  • the structuring agent tends to assist in the formation of the liquid crystalline gel network structures.
  • the structuring agent may also function as an emulsifier or surfactant.
  • Preferred compositions of this invention comprise from about 1% to about 20%, more preferably from about 1% to about 10%, most preferably from about 2% to about 9%, of one or more structuring agents.
  • Preferred structuring agents are those having an HLB of from about 1 to about 8 and having a melting point of at least about 45 C°.
  • Suitable structuring agents are those selected from the group consisting of saturated C14 to C30 fatty alcohols, saturated C16 to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C16 to C30 diols, saturated C16 to C30 monoglycerol ethers, saturated C16 to C30 hydroxy fatty acids, C14 to C30 hydroxylated and nonhydroxylated saturated fatty acids, C14 to C30 saturated ethoxylated fatty acids, amines and alcohols containing from about 1 to about 5 moles of ethylene oxide diols, C14 to C30 saturated glyceryl mono esters with a monoglyceride content of at least 40%, C14 to C30 saturated polyglycerol esters having from about 1 to about 3 alkyl group and from about 2 to about 3 saturated glycerol units, C14 to C30
  • the preferred structuring agents of the present invention are selected from the group consisting of stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
  • More preferred structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof.
  • Even more preferred structuring agents are selected from the group consisting of stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth-2, and mixtures thereof.
  • compositions of the present invention can also comprise a thickening agent, preferably from about 0.1% to about 5%, more preferably from about 0.1% to about 3%, and most preferably from about 0.25% to about 2%, of a thickening agent.
  • Nonlimiting classes ofthickening agents include those selected from the group consisting of:
  • These polymers are crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol.
  • the preferred carboxylic acid polymers are of two general types.
  • the first type of polymer is a crosslinked homopolymer of an acrylic acid monomer or derivative thereof (e.g., wherein the acrylic acid has substituents on the two and three carbon positions independently selected from the group consisting of C1-4 alkyl, —CN, —COOH, and mixtures thereof).
  • the second type of polymer is a crosslinked copolymer having a first monomer selected from the group consisting of an acrylic acid monomer or derivative thereof (as just described in the previous sentence), a short chain alcohol (i.e., a C1-4) acrylate ester monomer or derivative thereof (e.g., wherein the acrylic acid portion of the ester has substituents on the two and three carbon positions independently selected from the group consisting of C1-4 alkyl, —CN, —COOH, and mixtures thereof), and mixtures thereof, and a second monomer which is a long chain alcohol (i.e.
  • acrylate ester monomer or derivative thereof e.g., wherein the acrylic acid portion of the ester has substituents on the two and three carbon positions independently selected from the group consisting of C1-4 alkyl, —CN, —COOH, and mixtures thereof. Combinations of these two types of polymers are also useful herein.
  • the monomers are preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid, and mixtures thereof, with acrylic acid being most preferred.
  • the acrylic acid monomer or derivative thereof is preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid, and mixtures thereof, with acrylic acid, methacrylic acid, and mixtures thereof being most preferred.
  • the short chain alcohol acrylate ester monomer or derivative thereof is preferably selected from the group consisting of C1-4 alcohol acrylate esters, C1-4 alcohol methacrylate esters, C1-4 alcohol ethacrylate esters, and mixtures thereof, with the C1-4 alcohol acrylate esters, C1-4 alcohol methacrylate esters, and mixtures thereof, being most preferred.
  • the long chain alcohol acrylate ester monomer is selected from C8-40 alkyl acrylate esters, with C10-30 alkyl acrylate esters being preferred.
  • the crosslinking agent in both of these types of polymers is a polyalkenyl polyether of a polyhydric alcohol containing more than one alkenyl ether group per molecule, wherein the parent polyhydric alcohol contains at least 3 carbon atoms and at least 3 hydroxyl groups.
  • Preferred crosslinkers are those selected from the group consisting of allyl ethers of sucrose and allyl ethers of pentaerythritol, and mixtures thereof.
  • Examples of commercially available homopolymers of the first type useful herein include the carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol.
  • the carbomers are available as the Carbopol® 900 series from B.F. Goodrich (e.g., Carbopol® 954).
  • Examples of commercially available copolymers of the second type useful herein include copolymers of C10-30 alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain (i.e. C1-4 alcohol) esters, wherein the crosslinking agent is an ally ether of sucrose or pentaerytritol.
  • copolymers are known as acrylates/C10-30 alkyl acrylate crosspolymers and are commercially available as Carbopol® 1342, Carbopol® 1382Pemulen TR-1, and Pemulen TR-2, from B. F. Goodrich.
  • carboxylic acid polymer thickeners useful herein are those selected from the group consisting of carbomers, acrylates/C10-C30 alkyl acrylate crosspolymers, and mixtures thereof.
  • crosslinked polyacrylate polymers useful as thickeners or gelling agents include both cationic and nonionic polymers, with the cationics being generally preferred.
  • suitable crosslinked polyacrylate polymers are disclosed in U.S. Pat. No. 5,968,528.
  • polyacrylamide polymers especially non-ionic polyacrylamide polymers including substituted branched or unbranched polymers.
  • These polymers can be formed from a variety of monomers including acrylamide and methacrylamide which are unsubstituted or substituted with one or two alkyl groups (preferably C1 to C5).
  • acrylate amide and methacrylate amide monomers in which the amide nitrogen is unsubstituted, or substituted with one or two C1 to C5 alkyl groups (preferably methyl, ethyl, or propyl), for example, acrylamide, methacrylamide, N-methacrylamide, N-methylmethacrylamide, N,N-dimethylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide, and N,N-dimethylacrylamide.
  • These polymers have a molecular weight greater than about 1,000,000 preferably greater than about 1,5000,000 and range up to about 30,000,000.
  • Most preferred among these polyacrylamide polymers is the non-ionic polymer given the CTFA designation polyacrylamide and isoparaffin and laureth-7, available under the Tradename Sepigel 305 from Seppic Corporation (Fairfield, N.J.).
  • polyacrylamide polymers useful herein include multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids.
  • Commercially available examples of these multi-block copolymers include Hypan SR150H, SS500V, SS500W, SSSA100H, from Lipo Chemicals, Inc., (Patterson, N.J.).
  • polysaccharides are useful herein.
  • polysaccharides are meant gelling agents containing a backbone of repeating sugar (i.e. carbohydrate) units.
  • Nonlimiting examples of polysaccharide gelling agents include those selected from the group consisting of cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof.
  • alkyl substituted celluloses are also useful herein.
  • the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C10-C30 straight chain or branched chain alkyl group through an ether linkage.
  • these polymers are ethers of C10-C30 straight or branched chain alcohols with hydroxyalkylcelluloses.
  • alkyl groups useful herein include those selected from the group consisting of stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, cocoyl (i.e.
  • alkyl groups derived from the alcohols of coconut oil palmityl, oleyl, linoleyl, linolenyl, ricinoleyl, behenyl, and mixtures thereof.
  • Preferred among the alkyl hydroxyalkyl cellulose ethers is the material given the CTFA designation cetyl hydroxyethylcellulose, which is the ether of cetyl alcohol and hydroxyethylcellulose. This material is sold under the tradename Natrosol® CS Plus from Aqualon Corporation.
  • additional thickening and gelling agents useful herein include materials which are primarily derived from natural sources.
  • Nonlimiting examples of these gelling agent gums include materials selected from the group consisting of acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboyxmethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.
  • thickening and gelling agents useful herein include crosslinked copolymers of alkyl vinyl ethers and maleic anhydride.
  • Crosslinked polyvinyl(N-pyrrolidones) useful herein as additional thickening and gelling agents typically contain from about 0.25% to about 1% by weight of a crosslinking agent selected from the group consisting of divinyl ethers and diallyl ethers of terminal diols containing from about 2 to about 12 carbon atoms, divinyl ethers and diallyl ethers of polyethylene glycols containing from about 2 to about 600 units, dienes having from about 6 to about 20 carbon atoms, divinyl benzene, vinyl and allyl ethers of pentaerythritol, and the like.
  • a crosslinking agent selected from the group consisting of divinyl ethers and diallyl ethers of terminal diols containing from about 2 to about 12 carbon atoms, divinyl ethers and diallyl ethers of polyethylene glycols containing from about 2 to about 600 units, dienes having from about 6 to about 20 carbon atoms, divinyl
  • compositions of the present invention include a thickening agent selected from the group consisting of carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof, more preferably selected from the group consisting of crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof.
  • compositions of the present invention may comprise a wide variety of optional components, provided that such optional components are physically and chemically compatible with the essential components described herein, and do not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention.
  • Optional components may be dispersed, dissolved or the like in the carrier of the present compositions.
  • compositions may include, in addition to the essential components of the invention, absorbents (including oil absorbents such as clays an polymeric absorbents), abrasives, anticaking agents, antifoaming agents, antimicrobial agents (e.g., a compound capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes and useful, for example, in controlling acne and/or preserving the topical composition), binders, biological additives, buffering agents, bulking agents, chemical additives, cosmetic biocides, denaturants, cosmetic astringents, drug astringents, external analgesics, film formers, humectants, opacifying agents, fragrances, perfumes, pigments, colorings, essential oils, skin sensates, emollients, skin soothing agents, skin healing agents, pH adjusters, plasticizers, preservatives, preservative enhancers, propellants, reducing agents,
  • absorbents including oil absorbents such as clay
  • the composition of the invention may comprise an emollient.
  • the emollient may be selected from one or more of the following classes: Triglyceride esters which include, but are not limited to, vegetable and animal fats and oils such as castor oil, cocoa butter, safflower oil, cottonseed oil, corn oil, olive oil, cod liver oil, almond oil, avocado oil, palm oil, sesame oil, squalene, kikui oil and soybean oil; Acetoglyceride esters, such as acetylated monoglycerides; Ethoxylated glycerides, such as ethoxylated glyceryl monostearate; Alkyl esters of fatty acids having 10 to 20 carbon atoms which include, but are not limited to, methyl, isopropyl, and butyl esters of fatty acids such as hexyl laurate, isohexyl laurate, isohexyl palmitate, isopropyl palmitate,
  • the composition may comprise humectants, e.g., of the polyhydric alcohol-type.
  • Typical polyhydric alcohols include polyalkylene glycols and more preferably alkylene polyols and their derivatives, including propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, erythritol, threitol, pentaerythritol, xylitol, glucitol, mannitol, hexylene glycol, butylene glycol (e.g., 1,3-butylene glycol), hexane triol (e.g., 1,2,6-hexanetriol), glycerol, ethoxylated glycerol, propoxylated glycerol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate
  • guanidine e.g. ammonium and quaternary alkyl ammonium
  • lactic acid and lactate salts e.g. ammonium and quaternary alkyl ammonium
  • aloe vera in any of its variety of forms (e.g., aloe vera gel); sugar and starch derivatives (e.g., alkoxylated glucose); hyaluronic acid and derivatives thereof (e.g., salt derivatives such as sodium hyaluraonate); lactamide monoethanolamine; acetamide monoethanolamine; urea; panthenol; sugars; starches; silicone fluids; silicone gums; and mixtures thereof.
  • propoxylated glycerols are also useful.
  • hydrophilic and lipophilic creams were investigated. These creams are made up of highly biocompatible ingredients.
  • the lipid phases of these cream systems may be made up of any vegetal oil, such as olive oil, sweet almond oil, avocado oil, jojoba oil and others, of mineral oils, such as vaseline or others, and/or of any synthetic oil phase, such as esters of fatty acids, short, medium and long chain triglycerides.
  • dermatologically acceptable surfactants that are able to provide a certain physicochemical stability to creams may be used, e.g. lecithin, tween 80 and the like.
  • Gel-based formulations were also investigated as potential formulations for the topical application of valproic acid, its salts and derivatives.
  • Gels can be prepared by using any viscosizing agent that is able to provide the desired rheological features to formulations. Also in this case, agents to be used for the preparation of gel-based formulations must have a certain human skin tolerability, i.e. sepigel, zilgel, carbopol, xantan gum, gelatin, PVP, PEO and the like.
  • Specific topical dose levels for any particular patient may be employed depending upon a variety of factors including the age, body weight, general health, sex, diet, and prior medication, and the severity of the particular disease of the patient, and the activity of specific compounds employed, time of administration, rate of excretion, the duration of the treatment, other drugs, compounds, and/or materials used in combination. It will be appreciated that the appropriate dosage of the active compounds, and compositions comprising the active compounds, can vary from patient to patient. Determining the optimal dosage will generally involve balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention.
  • Topical administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosages of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
  • a suitable dose of the active compound i.e., VPA or a VPA derivative
  • the active ingredient is a salt, an ester, prodrug, or the like
  • the amount administered is calculated on the basis the parent compound and so the actual weight to be used is increased proportionately.
  • a suitable dose of this active compound is in the range of at least 0.1% by weight, preferably 0.1% to 6% per weight, more preferably 0.3% to 5%, more preferably 0.5% to 4% and even more preferably 1% to 4% per weight and for the retinoid used a suitable dose of the active compound is in the range of about 0.01% to about 1% by weight, preferably 0.05% to 0.5% per weight.
  • a suitable dose of the active compound is in the range of at least 0.1% by weight, preferably 0.1% to 6% per weight, more preferably 0.3% to 5%, more preferably 0.5% to 4% and even more preferably 1% to 4% per weight and for 5-Fluorouracil a suitable dose of the active compound is in the range of about 0.1% to about 10% by weight, preferably 1% to 10% per weight.
  • VPA is used topically applied once to three times daily at an accumulated total daily dose of 0.5 mg (milligram) to 10 mg (milligram) per lesion of approximately 1 cm 2 (qcm). In a more preferred embodiment, VPA is used topically applied once to three times daily at an accumulated total daily dose of 1 mg (milligram) to 8 mg (milligram) per lesion of approximately 1 cm 2 (qcm). In an even more preferred embodiment, VPA is used topically applied once to three times daily at an accumulated total daily dose of 2 mg (milligram) to 6 mg (milligram) per lesion of approximately 1 cm 2 (qcm).
  • the actual daily dose depends on the size of the lesion treated, and accordingly increases with increased lesion size, including lesion sizes of up to approximately 100 cm 2 (qcm) with according increases of daily doses.
  • the topical formulation containing VPA is made up by one of the three following formulations containing the listed ingredients (content is presented as % [w/w]):
  • White mineral oil 20 Cetyl Alcohol 24 Cetomacrogol 1000 6 Valproic Acid >0.1, e.g., 0.1 to 6 White vaseline add to 100
  • HaCaT cells human immortalized keratinocytes
  • MTT assay This calorimetric assay detects the formation of formazan which is proportional to the number of cells present. Tissue culture medium containing drugs was removed and 200 ⁇ l of DME containing 2 mg/ml MTT ((3-4, 5-dimethyl thiazol-2yl) 2,5-diphenyltetrazolium bromide) was added to each well. 96-well plates were incubated at 37 ° C., and 10% CO 2 for 30 minutes. Medium containing MTT was then removed and the cells were washed once with PBS. Following removal of the PBS, 200 ⁇ L DMSO was added to each well and plates were placed on a rotating platform shaker for 5 minutes. Results were obtained by reading the absorbance at a wavelength of 550 nm using a spectrophotometer. Results are expressed as percentages setting the control as 100%.
  • Apoptosis assays Apoptosis was measured by a Beckton Dickinson FACScalibur flow cytometer by analysing the percentage of Sub-G1 DNA containing cells. 10000 events were recorded for each sample. The amplification scale was linear for all parameters. Photomultiplier tension was set as to place the peak DNA content corresponding cells in G0/G1 at channel 300 in the FL2-H vs SCC—H graphs. Cells showing a less than peak DNA content (hypodiploid cells) and high SSC—H (granular high condensed cells) were regarded as apoptotic. The experiments were repeated three times in duplicate. Error bars represent 1 standard deviation.
  • FIG. 1 graphically depicts the results of growth assays performed on human immortalized keratinocytes (HaCaT cells), treated for three days with the indicated compounds. Drugs were added on the same day of plating (day 0). The MTT assay (to measure cell proliferation) was carried out on day 3. Various combinations of the drugs were used in the growth assays. As can be seen, VPA and Tazarotene used alone inhibited cell growth, and the combinations of Tazarotene plus the histone deacetylase inhibitor VPA were even more effective at inhibiting cell growth than the inhibition of both drugs alone as measured by the MTT assay.
  • VPA potentiates Tazarotene induced apoptosis in HaCaT cells ( FIG. 5 ).
  • Cells were plated in 35 mm diameter wells on day 0. Drugs were added on day 1. The apoptosis assay was carried out on day 2.
  • VPA induced a clear increase in subG1 DNA content, indicating that it induces apoptosis of human immortalized keratinocytes HaCaT.
  • the combinations of Tazarotene plus VPA were more effective at inducing apoptosis, than the apoptosis rate seen with both drugs used alone.
  • the combinatorial activity of these two drugs must be explained via synergistic activity of this treatment.
  • HaCaT cells human immortalized keratinocytes
  • RA Retinoic Acid
  • FIG. 2 Synergistic cell growth inhibition and induction of apoptosis in human immortalized keratinocytes (HaCaT cells) upon treatment with VPA or Retinoic Acid (RA) alone and by the combination of VPA and Retinoic Acid (RA) ( FIG. 2 ).
  • VPA and RA used alone inhibited growth of human keratinocytes HaCaT, and VPA even potentiated RA induced cell growth inhibition when both drugs are used in combination.
  • Cells were plated in wells on day 0. Then, drugs were added at the concentrations indicated (VPA1+RA1: VPA 1 mM+Retinoic Acid 1 ⁇ M, VPA1+RA2: VPA 1 mM+Retinoic Acid 2 ⁇ M).
  • the MTT assay was carried out on day 3.
  • Various combinations of the drugs were also used in the growth assays.
  • HaCaT cells human immortalized keratinocytes
  • 5-FU 5-Fluorouracil
  • VPA and 5-FU used alone inhibited growth of HaCaT cells, and VPA potentiated 5-FU induced growth inhibition in these cells when both drugs were used in combination ( FIG. 3 ).
  • Drugs were added on the same day of plating (day 0).
  • the MTT assay (to measure cell proliferation) was carried out on the third day. 5 ⁇ M or 10 ⁇ M 5-FU and 1 mM VPA were used.
  • the combinations of 5-FU plus the HDAC inhibitor VPA were more effective at inhibiting cell growth than each drug used alone as measured by MTT assay. Thus, this combinatorial activity of these two drugs must be explained via synergistic activity of this treatment.
  • VPA induces cell cycle arrest in human immortalized keratinocytes (HaCaT cells) ( FIG. 4 ).
  • BrdU incorporation assays Cell proliferation was detected by labeling cells with BrdU. After 24 hours treatment with VPA at the indicated concentrations, cells were incubated with BrdU (1:100) according to the protocol of the manufacturer (ZYMED, San Francisco, Calif.). Cells were incubated for 1 hour in the culture medium and then fixed with 70% ethanol. The incorporated BrdU was detected by the indirect immunoperoxidase method (Amersham, Arlington Heights, Ill.). Briefly, the culture cells were first incubated for 1 hour with Biotin-Mouse Anti-BrdU antibody.
  • TTBS buffer (20 mM Tris, 500 mM NaCl, 0.05% Tween-20, pH 7.5
  • the cells were further incubated with Biotinylated goat anti-mouse immunoglobulins for 10 min. Cells were then washed and incubated with enzyme (peroxidase) conjugate for 10 min at room temperature. Immunoreactivity was revealed by the addition of substrate-chromogen. The positive cells were counted on 10 randomly picked microscopic fields.
  • HaCaT cells were plated in 35 mm diameter wells on day 0.
  • VPA was added at the indicated concentrations on day 0.
  • the BrdU assay was carried out on day 2.
  • VPA produces a dose-dependent reduction of BrdU positive cells indicating that it induces cell cycle arrest and/or loss of cell viability of human keratinocytes.
  • VPA applied topically at 3% (w/w) permeates human skin in a time-dependent manner ( FIG. 6 ).
  • a topical sodium valproate formulation was prepared by dispersing Sepigel (Sepic, Milan Italy) (2% w/w) and sodium valproate (3% w/w) in the opportune amount of distilled water with constant stirring at room temperature. The resulting gel was stored at room temperature for 24 h prior to use.
  • In vitro skin permeation assay The analyses were carried out using a Franz type glass diffusion cell (LGA, Berkeley, Calif., USA) assembled with membranes carrying stratum corneum and epidermis (SCE).
  • SCE stratum corneum and epidermis
  • Adult human skin samples (mean age 29 ⁇ 5 years) were obtained from abdominal reduction surgery. Subcutaneous fat was trimmed and the skin samples were immersed in distilled water at 60° C. for 1 min; then stratum corneum and epidermis (SCE) were peeled off
  • SCE samples were dried at room temperature in a desiccator maintained at approximately 25% relative humidity. The dried samples were wrapped in aluminium foil and stored at 4° C. until use. Samples of dried SCE were rehydrated by immersion in distilled water at room temperature for 1 h before being mounted in Franz diffusion cells.
  • the exposed skin surface area was 0.75 cm and the receptor volume was 4.5 ml.
  • the receiving solution a solution of NaCl 0.9% (w/w)
  • Skin barrier integrity of the SCE membranes used in this protocol was assessed by determining their tritiated water permeability coefficient (Kp). Kp values were found to be 1.58 ⁇ 0.3 ⁇ 10 ⁇ 3 cm h ⁇ 1 and were in accord with those previously reported in the corresponding literature (Bronaugh et al., 1986, J Invest Dermatol 87, 451-3).
  • Sodium valproate (Valproate) was applied at 3% (w/w) topically to the skin surface. Each experiment was run in duplicate on three different skin donors.
  • FIG. 6 shows the results of an in vitro permeation assays.
  • Adult human skin samples skin surface area was 0.75 cm 2 ) were prepared as described in the methods section.
  • An appropriate amount of sodium valproate (Valproate) at 3% (w/w) was applied topically to the skin surface placed in the Franz type glass diffusion cells.
  • Each experiment was run in duplicate on three different skin donors. Samples of the receiving solution were withdrawn at different times during the experimental period (10 h); the sample volumes were replaced with the same amounts of fresh solution. All samples were analyzed for sodium valproate contents by means of an HPLC with spectrofluorimetric detection. The results were expressed as total amount permeated (mg).
  • VPA topically applied at 3% (w/w) permeates the skin in a time dependent manner. Thus, VPA is able to penetrate human skin effectively if applied topically.
  • VPA induces histone H4 acetylation in human immortalized keratinocytes (HaCat cells) in a concentration-dependent manner ( FIG. 7 ).
  • the upper panel shows a representative anti-acetylated histone H4 immunoblotting of total cell lysate from HaCaT cells which were treated as indicated.
  • the lower panel shows an anti-actin immunoblotting of a replica gel as loading control.
  • Cells were plated in 6 well plates at day 0. Drugs were added on day 1, cells were lysed on day 2 with RIPA buffer plus protease inhibitors. 40 ⁇ g of total cell lysate were separated by 12.5% SDS PAGE and subjected to immunoblotting with the indicated antibodies.
  • VPA induces histone H4 hyperacetylation in a dose dependent manner.
  • VPA topically applied at 3% (w/w) induces acetylation of histone H4 in nuclei of murine skin cells ( FIGS. 8 and 9 ) and human Basal Cell Carcinoma (BCC) cells ( FIG. 10 ).
  • VPA Valproate
  • 3% (w/w) a placebo formulation
  • a placebo formulation were applied to the skin of athymic nude mice.
  • VPA applied at 3% (w/w), or a placebo formulation were applied topically to BCC lesions of patients 16-20 hours before surgical excision.
  • Cryostat skin sections of 3 ⁇ m thickness were fixed in acetone at room temperature for 10 min.
  • the specimens were incubated with the rabbit anti-mouse serum and treated with APAAP (alkaline phosphatase anti-alkaline phosphatase) immunocomplex as described above.
  • APAAP alkaline phosphatase anti-alkaline phosphatase
  • the positive staining was developed in red color with naphthol-AS-BI phosphate as a substrate, and New Fuchsin (Dako) as a chromogen.
  • Pictures were taken with a digital camera connected to a light microscopy apparatus.
  • VPA potentiates the effects of Tazarotene in the treatment of superficial BCC's as can be seen in pictures of three representative patients before and after 6 weeks of topical treatment with Tazarotene applied at 0.1% (w/w) and VPA applied at 3% (w/w) ( FIG. 11 ).
  • VPA can potentiate the effect of other compounds (such as Tazarotene) on tumor cells, particularly of tumors of the skin, and show that—in the case of Tazarotene-resistant BCC—VPA may convert a resistant form of a tumor into a sensitive one.
  • Tazarotene-resistant BCC Tazarotene-resistant BCC
  • inflammatory cytokines Modulation of the expression of immunologically relevant proteins such as inflammatory cytokines. Treatment of human immortalized keratinocytes and peripheral blood lymphocytes with different HDAC inhibitors results in a reduction of inflammatory cytokines (FIGS. 12 to 16 ).
  • HaCaT cells Human immortalized keratinocytes (HaCaT cells) were seeded at a density of 2.5 million cells per ml into 75 cm 2 flasks. Cells were either left untreated or preincubated with 200 nM trichostatin A (TSA) or 5 mM valproic acid (VPA) for 4 hours at 37° C. followed by subsequent stimulation with lipopolysaccharide (LPS) (100 ng/ml). After 24 hours at 37° C. cells were lysed and total RNA was isolated using the RNeasy mini kit from Qiagen.
  • TSA trichostatin A
  • VPA mM valproic acid
  • LPS lipopolysaccharide
  • Monocyte and macrophage depleted peripheral blood mononuclear cells were obtained from consenting adults via separation using Ficoll-Hypaque.
  • the peripheral blood mononuclear cells (PBMC) fraction was washed and seeded in 9 cm petri dishes. After an incubation of 2 hours at 37° C. to remove most of the monocytes, macrophages, and B-cells, the non-adherent cells were collected and cultured in 175 cm 2 flasks for 2 days. Cells were harvested and adjusted to 3 million cells per ml. Aliquots of 500 ⁇ l were transferred to each well of 24-well flat bottom plates. Peripheral blood lymphocytes (PBL's) were treated with various concentrations of HDAC inhibitors as indicated.
  • PBL's Peripheral blood lymphocytes
  • TSA and other HDAC inhibitors Treatment of cells with TSA and other HDAC inhibitors leads to histone hyperacetylation and modulation of transcription. Therefore, we studied the effect of TSA and other HDAC inhibitors on the expression level of cytokine mRNA by semi-quantitative RT-PCR analysis and cytokine secretion by ELISA.
  • HaCaT Human immortalized keratinoyctes
  • TSA or VPA human immortalized keratinoyctes
  • LPS was used to induce cytokine production.
  • the level of cytokine mRNA expression is shown by semi-quantitative RT-PCR ( FIG. 12 ). Agarose gel electrophoresis of the RT-PCR products showed a significant decrease in the level of TNF- ⁇ and IL-6 mRNA in TSA and VPA treated cells compared to untreated, but stimulated control ( FIG. 12A ). Under these conditions GAPDH mRNA as internal control remained unaffected.
  • the induction of IFN- ⁇ by LPS stimulation was only moderate, the mRNA transcript of IFN- ⁇ was virtually unaffected by exposure to TSA, but significantly reduced by VPA.
  • FIG. 12B shows the effect of TSA and VPA on IL-4 and IL-6 mRNA transcripts.
  • TSA peripheral blood lymphocytes
  • VPA peripheral blood lymphocytes
  • FIG. 13 A and B show that other HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA), G2M-701, G2M-702, and G2M-707 can modulate cytokine expression.
  • SAHA suberoylanilide hydroxamic acid
  • G2M-701, G2M-702, and G2M-707 can modulate cytokine expression.
  • FIG. 14 the effect of HDAC inhibitors on IL-2 and IFN- ⁇ transcription level was even more striking when T-cells were activated by the T cell receptor complex using CD3 and CD28 antibodies as shown in FIG. 14 .
  • PBL's were preincubated with the HDAC inhibitors TSA, SAHA, VPA, G2M-701 or the anti-inflammatory steroid Dexamethasone (Dex), VPA and G2M-701 were used in two different concentrations.
  • the cells were activated via the T cell receptor complex (TCR/CD3) using CD3 and CD28 antibodies for 24 hours.
  • TCR/CD3 T cell receptor complex
  • FIGS. 14A and B the mRNA transcripts of several cytokines were significantly reduced by all HDAC inhibitors used with minor differences.
  • FIG. 14A and B the mRNA transcripts of several cytokines were significantly reduced by all HDAC inhibitors used with minor differences.
  • FIG. 14C shows a western blot analysis using antibodies against acetylated histone H3 and acetylated H4 as well as ⁇ -actin as a control for equal loading displaying the successful induction of histone hyperacetylation by HDAC inhibitors.
  • HDAC inhibitors such as VPA, G2M-701, G2M-702, and G2M-707 inhibit the PMA/Ion ( FIGS. 12, 13 and 16 ) and TCR/CD3 ( FIGS. 14, 15 , and 16 ) mediated induction of cytokine expression in human T lymphocytes and human keratinocytes.
  • HDAC inhibitors have the potential to modify cytokine expression in response to cellular activation. They are able to block expression of several cytokine transcripts abolishing immunological important inflammatory cytokine production. The dramatic down-regulation of cytokine secretion by HDAC inhibitors supports their potential use as a therapeutic agent.
  • VPA which acts as preferential inhibitor of histone deacetylase class I enzymes, induces histone hyperacetylation in cellular systems as well as in peripheral blood cells of patients.
  • Peripheral blood cells from patients treated with VPA were obtained before, 6 h, 24 h, and 48 h after start of VPA treatment (see treatment schedule, FIG. 17 ).
  • Whole cell extracts were prepared by lysis of cells in RIPA buffer including protease inhibitors. Lysates were separated by SDS gel electrophoresis and transferred onto PVDF membranes. Acetylated histones H3 and H4 and the marker gene HDAC-2 were detected by western blot analysis using an anti-acetylated H3 antibody (Upstate, #06-942), an anti-acetylated H4 antibody (clon T25; patent application EP 02.021984.6), and an anti-HDAC-2 antibody (SCBT, SC-7899). As an equal loading control PVDF membranes were stained with Coomassie ( FIG. 18 ).
  • Peripheral blood cells from patient treated with VPA before, 6 h, 24 h, and 48 h after start of VPA treatment were seeded into a 24-well flat bottom plate with a density of 1 million cells per ml. The cells were either left unstimulated or stimulated with CD3 and CD28 antibodies. After 24 hours at 37° C. the supernatant was collected and the secretion of IL-2 and TNF- ⁇ was quantified by ELISA (R&D Systems) ( FIGS. 19A and B).
  • RNA from unstimulated and CD3/CD28 stimulated cells was isolated using the RNeasy mini kit (Qiagen). One microgram of total RNA was converted to cDNA by standard methods using reverse transcriptase and an oligo-dT primer (Invitrogen). For semiquantitative PCR, 2 ⁇ l of cDNA were amplified by PCR using the specific primers as described above ( FIG. 19C ).
  • FIG. 18 The Western Blot analysis with the peripheral blood cell lysates shows the detection of Histone H3 and H4 hyperacetylation and down-regulation of the marker protein HDAC-2 with serum levels above the therapeutic plasma concentration.
  • the induction of histone hyperacetylation and down-regulation of HDAC-2 clearly demonstrated the efficacy of the VPA treatment and shows that VPA can be used in patients to reach effective therapeutic serum concentrations inducing histone hyperacetylation in peripheral blood cells and regulation of a target gene HDAC-2.
  • VPA modulates the expression of inflammatory cytokines such as IL-2 and TNF- ⁇ in the culture supernatant as assayed by ELISA ( FIGS.
  • FIG. 18A , and B consistent with a decrease in IL-2 and TNF- ⁇ mRNA transcripts in CD3/CD28 stimulated cells ( FIG. 18C ). Furthermore, it significantly reduced the cytokine mRNA expression of IL-4 and IFN- ⁇ starting at 24 hours of VPA treatment.
  • VPA can efficiently modulate immunologically relevant genes such as IL-2, TNF- ⁇ , IL-4 and IFN- ⁇ in a patient treated with the HDAC inhibitor VPA according to the treatment schedule depicted in FIG. 17 .
  • VPA and other HDAC inhibitors to act as immune modulating compounds supports this invention to employ these compounds as anti-inflammatory drugs for the therapy of disorders linked to pathologically overactive immune cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/275,258 2003-06-25 2005-12-21 Topical Use of Valproic Acid for the Prevention or Treatment of Skin Disorders Abandoned US20060160897A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20030014278 EP1491188A1 (en) 2003-06-25 2003-06-25 Topical use of valproic acid for the prevention or treatment of skin disorders
EP03014278.0 2003-06-25
PCT/EP2004/006789 WO2005000289A1 (en) 2003-06-25 2004-06-23 Topical use of valproic acid for the prevention or treatment of skin disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006789 Continuation WO2005000289A1 (en) 2003-06-25 2004-06-23 Topical use of valproic acid for the prevention or treatment of skin disorders

Publications (1)

Publication Number Publication Date
US20060160897A1 true US20060160897A1 (en) 2006-07-20

Family

ID=33395866

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/275,258 Abandoned US20060160897A1 (en) 2003-06-25 2005-12-21 Topical Use of Valproic Acid for the Prevention or Treatment of Skin Disorders
US11/275,263 Expired - Fee Related US7892833B2 (en) 2003-06-25 2005-12-21 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions
US12/975,802 Abandoned US20110092447A1 (en) 2003-06-25 2010-12-22 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/275,263 Expired - Fee Related US7892833B2 (en) 2003-06-25 2005-12-21 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions
US12/975,802 Abandoned US20110092447A1 (en) 2003-06-25 2010-12-22 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions

Country Status (14)

Country Link
US (3) US20060160897A1 (es)
EP (4) EP1491188A1 (es)
JP (2) JP2008529964A (es)
AT (1) ATE409471T1 (es)
AU (2) AU2004251435B2 (es)
CA (2) CA2531107A1 (es)
CY (1) CY1108617T1 (es)
DE (1) DE602004016847D1 (es)
DK (1) DK1635808T3 (es)
ES (1) ES2310734T3 (es)
PL (1) PL1635808T3 (es)
PT (1) PT1635808E (es)
SI (1) SI1635808T1 (es)
WO (2) WO2005000282A2 (es)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037738A1 (en) * 2003-06-25 2007-02-15 Bernd Hentsch Using Inhibitors of Histone Deacetylases for the Suppression Therapy of Inherited Disease Predisposing Conditions
US20080194690A1 (en) * 2005-05-13 2008-08-14 Topotarget Uk Limited Pharmaceutical Formulations Of Hdac Inhibitors
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
US20100190694A1 (en) * 2009-01-14 2010-07-29 Jan Fagerberg Methods for identifying patients who will respond well to cancer treatment
US20100286279A1 (en) * 2007-09-25 2010-11-11 Topotarget Uk Limited Methods of Synthesis of Certain Hydroxamic Acid Compounds
US20110003777A1 (en) * 2008-03-07 2011-01-06 Topotarget A/S Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat
US20110052641A1 (en) * 2009-06-09 2011-03-03 Mardi Medicines Ltd. Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms
WO2013138075A1 (en) * 2012-03-14 2013-09-19 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US9427605B2 (en) 2005-03-24 2016-08-30 Novan, Inc. Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US10226483B2 (en) 2013-08-08 2019-03-12 Novan, Inc. Topical compositions and methods of using the same
US10265334B2 (en) 2011-07-05 2019-04-23 Novan, Inc. Anhydrous compositions
US10285959B2 (en) 2005-02-03 2019-05-14 Topotarget Uk Limited Combination therapies using HDAC inhibitors
WO2020069225A1 (en) * 2018-09-26 2020-04-02 Global Health Solutions Llc Phmb compositions and methods of treatment for skin cancer
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
CN113995742A (zh) * 2021-10-22 2022-02-01 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
JP4921351B2 (ja) * 2004-03-26 2012-04-25 ディーエスエム アイピー アセッツ ビー．ブイ． レチノイドと組み合せたｈｄａｃインヒビターを含む組成物
WO2006029818A2 (en) * 2004-09-16 2006-03-23 Dsm Ip Assets B.V. Cosmetic compositions containing an hydroxamic acid compound optionally in combination with a retinoid
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
GB0525680D0 (en) * 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
EP2049139A4 (en) 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER
CA2674309A1 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
EP2362865A2 (en) * 2008-10-28 2011-09-07 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
NZ706052A (en) 2010-07-12 2016-07-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CA2836940A1 (en) 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
JP2015515279A (ja) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
BR112017004893A2 (pt) 2014-09-10 2017-12-12 Univ Washington composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
EP3222324B1 (en) * 2016-03-23 2020-05-13 Wayne State University Valproate as a topical anti-fungal treatment
RU2628865C1 (ru) * 2016-10-24 2017-08-22 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения риска наследственной детерминированности рака молочной железы по анамнестическим данным

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
US6656905B1 (en) * 1998-10-13 2003-12-02 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
JP2002514161A (ja) * 1996-07-02 2002-05-14 バー イラン ユニバーシティー ガンおよび他の細胞増殖性疾患の治療に有用なレチノイルオキシ（置換）アルキレンブチレート
IT1284101B1 (it) * 1996-07-02 1998-05-08 Sigea Srl Sali di complessi anionici di ru(iii), utili in terapia come agenti antimetastatici e antineoplastici
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US5968528A (en) 1997-05-23 1999-10-19 The Procter & Gamble Company Skin care compositions
JPH11335284A (ja) * 1998-05-21 1999-12-07 Isehan:Kk レチノイド類を含有する皮膚外用剤
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
US6747061B2 (en) * 2000-03-21 2004-06-08 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
EP1170008A1 (en) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
DE60137932D1 (de) * 2000-07-17 2009-04-23 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
KR100843703B1 (ko) * 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
SI1311256T1 (sl) * 2000-08-17 2005-12-31 Teva Pharma Uporaba derivatov amidov valprojske kisline in amidov 2-valproenske kisline za zdravljenje ali preprecevanje bolecin in/ali glavobolnih motenj
KR20020050135A (ko) * 2000-12-20 2002-06-26 조명재 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물
JP2002284662A (ja) * 2001-03-27 2002-10-03 Kanebo Ltd 皮膚外用剤組成物
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2002315337A1 (en) * 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using valproate
ITMI20011733A1 (it) * 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
BR0213932A (pt) * 2001-11-06 2004-08-31 Novartis Ag Combinação do inibidor da ciclooxigenase-2/inibidor da desacetilase histona
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
ES2399880T3 (es) * 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
EP1547617B1 (en) * 2002-08-20 2010-04-28 Astellas Pharma Inc. Arthrodial cartilage extracellular matrix degradation inhibitor
EP1403639A1 (en) 2002-09-30 2004-03-31 G2M Cancer Drugs AG Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
EP1839656A1 (en) 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656905B1 (en) * 1998-10-13 2003-12-02 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892833B2 (en) 2003-06-25 2011-02-22 Topotarget Germany Ag Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions
US20070037738A1 (en) * 2003-06-25 2007-02-15 Bernd Hentsch Using Inhibitors of Histone Deacetylases for the Suppression Therapy of Inherited Disease Predisposing Conditions
US20110092447A1 (en) * 2003-06-25 2011-04-21 Bernd Hentsch Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions
US10285959B2 (en) 2005-02-03 2019-05-14 Topotarget Uk Limited Combination therapies using HDAC inhibitors
US10799469B2 (en) 2005-02-03 2020-10-13 Topotarget Uk Limited Combination therapies using HDAC inhibitors
US9427605B2 (en) 2005-03-24 2016-08-30 Novan, Inc. Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US8835501B2 (en) 2005-05-13 2014-09-16 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
US9856211B2 (en) 2005-05-13 2018-01-02 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
US20080194690A1 (en) * 2005-05-13 2008-08-14 Topotarget Uk Limited Pharmaceutical Formulations Of Hdac Inhibitors
US9957227B2 (en) 2005-05-13 2018-05-01 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
US8828392B2 (en) 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
US9603926B2 (en) 2005-11-10 2017-03-28 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors for the treatment of cancer
US20100286279A1 (en) * 2007-09-25 2010-11-11 Topotarget Uk Limited Methods of Synthesis of Certain Hydroxamic Acid Compounds
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
US20110003777A1 (en) * 2008-03-07 2011-01-06 Topotarget A/S Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat
US20100190694A1 (en) * 2009-01-14 2010-07-29 Jan Fagerberg Methods for identifying patients who will respond well to cancer treatment
US20110052641A1 (en) * 2009-06-09 2011-03-03 Mardi Medicines Ltd. Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms
US9283199B2 (en) 2009-06-09 2016-03-15 Cimas Limited Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms
US10376538B2 (en) 2009-08-21 2019-08-13 Novan, Inc. Topical gels and methods of using the same
US9737561B2 (en) 2009-08-21 2017-08-22 Novan, Inc. Topical gels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US10500220B2 (en) 2011-07-05 2019-12-10 Novan, Inc. Topical compositions
US10265334B2 (en) 2011-07-05 2019-04-23 Novan, Inc. Anhydrous compositions
AU2013232576B2 (en) * 2012-03-14 2016-09-01 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
WO2013138075A1 (en) * 2012-03-14 2013-09-19 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US10258564B2 (en) 2013-02-28 2019-04-16 Novan, Inc. Topical compositions and methods of using the same
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11285098B2 (en) 2013-02-28 2022-03-29 Novan, Inc. Topical compositions and methods of using the same
US10226483B2 (en) 2013-08-08 2019-03-12 Novan, Inc. Topical compositions and methods of using the same
US10828323B2 (en) 2013-08-08 2020-11-10 Novan, Inc. Topical compositions and methods of using the same
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
WO2020069225A1 (en) * 2018-09-26 2020-04-02 Global Health Solutions Llc Phmb compositions and methods of treatment for skin cancer
CN113995742A (zh) * 2021-10-22 2022-02-01 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途

Also Published As

Publication number Publication date
DK1635808T3 (da) 2009-01-05
PT1635808E (pt) 2008-11-20
SI1635808T1 (sl) 2009-04-30
AU2004251435A1 (en) 2005-01-06
PL1635808T3 (pl) 2009-02-27
CA2531101A1 (en) 2005-01-06
CY1108617T1 (el) 2014-04-09
US20070037738A1 (en) 2007-02-15
WO2005000282A3 (en) 2005-04-28
EP2039355A2 (en) 2009-03-25
EP1635798A2 (en) 2006-03-22
ATE409471T1 (de) 2008-10-15
WO2005000289A1 (en) 2005-01-06
JP2008529966A (ja) 2008-08-07
EP1635808B1 (en) 2008-10-01
EP2039355A3 (en) 2012-02-01
WO2005000282A2 (en) 2005-01-06
US20110092447A1 (en) 2011-04-21
AU2004251434A1 (en) 2005-01-06
JP2008529964A (ja) 2008-08-07
EP1491188A1 (en) 2004-12-29
DE602004016847D1 (de) 2008-11-13
AU2004251435B2 (en) 2010-12-02
EP1635808A1 (en) 2006-03-22
ES2310734T3 (es) 2009-01-16
US7892833B2 (en) 2011-02-22
CA2531107A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
EP1635808B1 (en) Topical use of valproic acid for the prevention or treatment of psoriasis and acne
EP2001458B1 (en) Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
Pradhan et al. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches
CN103732231B (zh) 炎性病症的预防和治疗
KR20010023186A (ko) 세포-매개된 면역 질환의 치료방법
WO2006138056A1 (en) Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
US20020187169A1 (en) Kavalactone compositions
WO2004073622A2 (en) Novel therapeutic method and compositions for topical administration
JP2011231128A (ja) 角層細胞分化正常化用皮膚外用剤
Pătraşcu et al. Ulcerated necrobiosis lipoidica to a teenager with diabetes mellitus and obesity
JPH09509139A (ja) 酪酸エステル細胞分化薬
US20060159648A1 (en) Novel therapeutic method and compositions for topical administration
FR2722985A1 (fr) Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations
JP2006342074A (ja) ヒト細胞の分化促進剤及びそれを含む製品
Dubey et al. Novel carriers and approaches: insight for psoriasis management
JP4974813B2 (ja) 痒みを寛解するための方法
Bissonnette et al. Modulation of mast cell function in the gastrointestinal tract
JP2001322990A (ja) 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物
CN104367547A (zh) 一种适用于口腔给药的缓控释替硝唑软膏
CN109195596A (zh) 组合物及其使用方法
JP2020045296A (ja) Ｍ．ａｅｒｉｌａｔａを有効成分とする皮膚外用組成物
RU2599289C2 (ru) Средства, стимулирующие регенерацию тканей
JP3816545B2 (ja) 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
WO2004073627A2 (en) Novel therapeutic method and compositions for topical administration
JPH0971539A (ja) 外用鎮痒剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: TOPOTARGET GERMANY AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELICCI, PIER GIUSEPPE;CHIMENTI, SERGIO;COSTANZO, ANTONIO;AND OTHERS;REEL/FRAME:017221/0859;SIGNING DATES FROM 20051224 TO 20051229

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION